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Abbreviations 
AAR   - Area at risk 
ADMA - Asymmetric dimethylarginine 
ANOVA - Analysis of variance 
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AP-1 - Activator protein 1 
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ATP - Adenosine triphosphate 
AV - Atrioventricular 
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b-TFE - balanced turbo field echo 
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dP/dtmax - Minimum rates of systolic pressure decline 
Ea - Arterial elastance 
Ea/Ees ratio - ventricular-arterial coupling 
ECMO - Extracorporeal membrane oxygenation 
ECG - Electrocardiogram 
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Ees - ventricular elastance 
EF - Ejection fraction 
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ERK - Extracellular signal-regulated kinase  
ETC - Mitochondrial electron transport chain 
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FDA - US Food and Drug Administration 
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GAF domain - This name derives from the first proteins it was found 
in:  cGMP-specific phosphodiesterases, adenylyl cyclases 
and FhlA 
Glu - Glutamic acid 
GSK3β - Glycogen synthase kinase 3β 
GTP - Guanosine triphosphate 
H-NOX - Heme-nitric oxide and oxygen binding 
H2S - Hydrogen sulfide 
HCN - Hyperpolarization-activated cyclic nucleotide-gated ion 
channels 
HIF-1α - Hypoxia-inducible factor-1α 
HSP70 - 70 kilodalton heat shock proteins 
IA - Infarcted area 
I/R - Ischemia reperfusion 
ICAM-1 - Intercellular Adhesion Molecule 1 
DOI:10.14753/SE.2016.1918
 8 
 
If - funny current 
IGF-1 - Insulin-like growth factor 1 
IL-1 - Interleukin 1 
iNO - Inhaled nitric oxide 
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iNO+TAD - Combination of inhaled nitric oxide and tadalafil 
IP - Intraperitoneal 
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IRAG - Inositol 1,4,5-trisphosphate (IP3) receptor-associated PKG 
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iv - intra venous 
IVSd - interventricular septum thickness at end-diastole 
IVSs - interventricular septum thickness at end-systole 
JAK - Janus-activated kinase 
JNK1 - c-Jun NH2-terminal kinase 1 
k-t BLAST - Broad-use Linear Acquisition Speed-up Technique 
LAD - Left anterior descending artery 
L-NMMA - NG-monomethyl-L-arginine 
LTCC - L-type Ca2+ channels 
LV - Left ventricle 
LVAD - Left ventricular assist device 
LVEDVi - Left ventricular end-diastolic volume index 
LVEF - Left ventricular ejection fraction 
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LVH - Left ventricular hypertrophy 
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MAPK - Mitogen-activated protein kinases 
DOI:10.14753/SE.2016.1918
 9 
 
MEKK1 - Mitogen-activated protein kinase kinase 
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MIP-1 /-2 - Macrophage Inflammatory Proteins 
mitoKATP - Mitochondrial ATP-sensitive K
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NOS - Nitric oxide synthase 
NOS1 - nitric oxide synthase 1 (also known as nNOS) 
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NOS3 - nitric oxide synthase 3 (also known as cNOS, eNOS) 
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p53 - cellular tumor antigen p53 
p70S6K - extracellular regulated kinase system with downstream p70 
ribosomal protein S6 kinase 
PAP - Pulmonary artery pressure 
PAS - Protein fold named for its association with the Per, ARNT, and 
Sim proteins 
PDE - Phosphodiesterase 
pGC - Particulate guanylate cyclase 
PI3K(p110α) - Phosphoinositide 3-kinase (p110α) 
PIP3 - Phosphatidylinositol 3,4,5-trisphosphate  
PKA - cAMP dependent protein kinase 
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PKG - cGMP dependent proteinkinase 
PPARα - peroxisome proliferator-activated receptor alpha 
PPHN - Persistent pulmonary hypertension of the new-born 
ppm - Parts-per-million, 10−6 
PRSW - Preload-recruited stroke work 
PV - pressure-volume 
PVR - Pulmonary vascular resistance 
RBBB - Right Bundle Branch Block 
RhoA - Ras homolog gene family member A 
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ROS - Reactive oxygen species 
RV - Right ventricle 
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RVEF - Right ventricular ejection fraction 
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RVMi - Right ventricular mass index 
RVSVi - Right ventricular stroke volume index 
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SAP - Systemic arterial pressure 
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SEM - Standard error of mean 
SERCA - Sarco/endoplasmic reticulum Ca2+-ATPase 
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STAT - Signal transducer and activator of transcription 
SV - Stroke volume 
SW - Stroke work 
Τ - isovolumic relaxation 
T2w-SPIR - Triggered blood suppressed T2-weighted spectral inversion 
recovery 
TAD - Tadalafil 
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VASP - Vasodilator-Stimulated Phosphoprotein 
VO2 - Maximal oxygen uptake 
VCAM-1 - Vascular cell adhesion protein 1 
XO - Xanthine oxidase 
XOR - Xanthine oxidoreductase 
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1. Introduction 
1.1. Nitric oxide (NO) signaling in cardiovascular physiology and 
pathophysiology 
1.1.1. Identification of NO 
Nitrogen oxide (NO) is not only an important intermediate in chemical industry, 
but an important signaling molecule as well. This free radical is a byproduct of 
combustion and is naturally produced during electrical discharges of lightning in 
thunderstorms (National Center for Biotechnology Information and U. S. National 
Library of Medicine, n.d.). 
It was first described in the 18th century by Joseph Priestly – an English polymath 
– in the first volume of his collection of his most important scientific texts: Experiments 
and Observations on Different Kinds of Air (Johnson et al., 1775). It took almost three 
centuries for this “nitrous air” to amaze the scientific world. Search for the mysterious 
endothelium-derived relaxing factor (EDRF) led to the recognition that despite being a 
gaseous molecule and a free radical NO is a key vertebrate biological messenger (Ignarro 
et al., 1987; Palmer et al., 1987). It became Molecule of the year in 1992 and in 1998 
Robert F. Furchgott, Louis C. Ignarro and Ferid Murad were awarded the Nobel Prize in 
Physiology or Medicine for their discoveries concerning nitric oxide as a signaling 
molecule in the cardiovascular system (“The Nobel Prize in Physiology or Medicine 
1998,” n.d.). 
1.1.2. General chemical and biological properties of NO 
Nitric oxide is an inorganic, odorless, colorless and only slightly water-soluble 
gas in radical form in statu nascendi, with rapid dimerization capacity. It is non-
flammable, but it will accelerate combustion and increase the risk of fire and explosion 
in combustible and flammable materials (Bhatraju et al., 2015; Bloch et al., 2007; 
National Center for Biotechnology Information and U. S. National Library of Medicine, 
n.d.). As a byproduct of combustion NO may reach significant concentrations in ambient 
or indoor air.  When exposed to oxygen NO is readily and rapidly oxidized to nitrogen 
dioxide (National Center for Biotechnologyr Information and U. S. National Library of 
Medicine, n.d.). 
DOI:10.14753/SE.2016.1918
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2 NO + O2 → 2 NO2 
1.1.3. General behaviour of NO in biological systems: toxicity and safety 
issues 
Nitric oxide has a half-life of seconds in biological fluids and is highly diffusible 
(Lei et al., 2013). It can get oxidized to nitrate and nitrite, react with superoxide to form 
peroxynitrite, nitrosylate thiol containing amino acids and react with heme containing 
proteins (Bhatraju et al., 2015; Bryan and Loscalzo, 2011; National Center for 
Biotechnology Information and U. S. National Library of Medicine, n.d.).  
Under normal circumstances absorption occurs through the eyes and lungs. (Nitric 
oxide levels can reach a concentration up to 1000ppm in tobacco smoke (Bryan and 
Loscalzo, 2011)!) After reaching the lower respiratory tract NO diffuses through the 
alveoli into the microvasculature and reacts with the hemoglobin in the erythrocytes. 
Methemoglobin is formed, which does not bind oxygen and impairs oxygen delivery 
(Bloch et al., 2007). Methemoglobin is rapidly reduced to ferrous hemoglobin and in the 
end nitrite and nitrate will be formed. The greater part of the nitrate, and thus the inhaled 
nitric oxide, is excreted into the urine and eliminated from the body (Kapil et al., 2010). 
In the presence of moisture and oxygen nitric and nitrous acid are formed and 
corrosive conditions develop, making NO a skin, eye and a mucous membrane irritant 
(National Center for Biotechnology Information and U. S. National Library of Medicine, 
n.d.). Clinical experience states that prolonged exposure to NO will result in rebound 
pulmonary hypertension after weaning of exposure (Bloch et al., 2007; Bryan and 
Loscalzo, 2011).  
When exposed to oxygen NO will form the pulmonary irritant nitrogen dioxide 
(NO2). The amount of NO2 formed depends on gas concentrations and the time reacting 
gasses are mixed (National Center for Biotechnology Information and U. S. National 
Library of Medicine, n.d.). 
1.1.4. Natural sources and protective effects of nitric oxide 
Nitric oxide is a known byproduct in almost all type of organisms. It is 
endogenously synthetized from L-arginine, oxygen and NADPH by various nitric oxide 
synthase enzymes (NOS) (Knowles and Moncada, 1994). NO production changes with 
DOI:10.14753/SE.2016.1918
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altitude changes (acute and chronic) and has heavy influence on altitude adaptation (Beall 
et al., 2012). 
An NOS independent way, the reduction of inorganic nitrate (nitrate → nitrite → 
nitric oxide) can also elevate nitric oxide levels. After consumption of nitrate rich 
vegetables facultative anaerobe bacteria reduce it to nitrite, which is then swallowed and 
absorbed (Kapil et al., 2010; Lundberg et al., 2011). Some enzymes, e.g. xanthine oxidase 
may contribute to the endogenous conversion of nitrate to nitrite (Lei et al., 2013; Zweier 
and Talukder, 2006). Nitrate elevation can lead to protection on both molecular (Table 
1.) and systematic levels resulting among others in cardo-protection, blood pressure 
reduction, beneficial modulation of hypercholesterolemia and increased exercise 
tolerance (Kapil et al., 2010; Lundberg et al., 2011; Phillips et al., 2009).  
 
Table 1. Chemical and molecular protective effects of nitric oxide.(Phillips et al., 2009) 
Effect as Description 
1. Antioxidant Free radical scavenger, inhibits cell 
respiration, restores antioxidant enzyme 
levels 
2. Anticytokines Suppresses TNF-α and IL-1 
3. Anti-adhesion molecules Inhibits selectins, VCAM-1 and ICAM-1 
4. Antiapoptotic Downregulates gene p53, inhibits human 
caspases, induces expression of HSP70 
5. Antichemokines Downregulates MIP-1 and MIP-2 
6. Antidetrimental signaling Regulates MAPKs, promotes 
preconditioning, produces elevated levels 
of cGMP 
7. Antinuclear proteins Inhibits NF-κB and AP-1 
 
1.1.5. Nitric oxide synthesis 
Arginine derived NO synthesis has been best studied in mammals and three 
isoforms of the NOS enzyme were identified (Knowles and Moncada, 1994). NOS 
oxidizes the guanidine group of L-arginine in a process that consumes five electrons and 
DOI:10.14753/SE.2016.1918
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results in the formation of NO with stoichiometric formation of L-citrulline. The process 
involves the oxidation of NADPH and the reduction of molecular oxygen. The 
transformation occurs at a catalytic site adjacent to a specific binding site of L-arginine. 
(Figure 1.) 
1.1.5.1. Endothelial nitric oxide synthase (eNOS) 
This isoform is also known as nitric oxide synthase 3 (NOS3) or constitutive NOS 
(cNOS) and is functionally similar to the nNOS, as both are clearly Ca2+- Calmodulin 
dependent. In humans it is encoded by the NOS3 gene and is partially membrane 
associated. Endothelial NOS generates NO in the blood vessels and is involved with 
vascular tone and platelet regulation (Knowles and Moncada, 1994). Huang et al. proved 
the elementary protective role of eNOS against hypertension and maintaining baseline 
bloodpressures (Huang et al., 1995). 
In myocytes eNOS binds with Caveolin-1 and Caveolin-3 and is localized in 
caveolae and both increased Ca2+ concentration and phosphorylation can activate it. 
NOS3 has his own unique localization and signaling pathway, which among others will 
influence myocyte contraction and action potential development (Tang et al., 2014). 
Several mutations of the eNOS gene are known that could display significant 
differences under different clinical conditions. The three most widely studied NOS-3 
polymorphisms in humans include the G894CT (Glu298Asp) in exon 7, the 4a/5b 27-
Figure 1.  NO synthesis. Oxidation of L-Arg to L-citrulline occurs via two successive 
mono-oxygenation reactions producing Nω-hydroxy-L-arginine (NOHLA) as an 
intermediate. 2 mol of O2 and 1.5 mol of NADPH are consumed per mole of NO formed. 
(Based on the work of Prof. Moncada)8  
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basepair variable number of tandem repeats in intron 4, and the T-786C variant in the 
promoter region (Pereira et al., 2007). These polymorphisms are associated with a variety 
of clinical conditions, e.g. atherosclerosis, hypertension, heart failure and adaptation to 
physical exercise (Lembo et al., 2001; Matsa et al., 2013; Pereira et al., 2007, p. 3; 
Wolfarth et al., 2008).  
Cardiomyocyte specific NOS3 overexpression preserved LV function and 
endothelial NOS3 overexpression improved survival and decreased pulmonary edema 
after myocardial infarction (Janssens et al., 2004; Jones et al., 2003). Potential therapeutic 
benefits of NOS3 overexpression and increased NO bioavailability were proven in gene 
transfer models. In chronic ischemia clinically relevant neovascularization was induced 
and it attenuated acute ischemia reperfusion injury and ischemic remodeling (Kupatt et 
al., 2007; Szelid et al., 2009). Overexpression of NOS3 in cardiomyocytes was also 
suggested to be protective against arrhythmias by restoring sympatho-vagal balance 
(Massion et al., 2004).  
1.1.5.2. Neuronal nitric oxide synthase (nNOS) 
Neuronal nitric oxide was the first isoform to be purified and cloned, is also known 
as NOS1 and is encoded in humans by the NOS1 gene. It is Ca2+- Calmodulin dependent 
and is constitutively expressed at high activity in the central and peripheral nervous 
system and in the human skeletal muscle as well. nNOS is responsible for the largest 
proportion of constitutive NOS activity in humans (Knowles and Moncada, 1994). In 
cardiomyocytes NOS1 is predominantly localized in the sarcoplasmic reticulum, signals 
through the cGMP independent pathway and acts as a major regulator of excitation 
contraction coupling and myocyte Ca2+ handling. NOS1 is necessary for the positive 
force-frequency response and β-adrenergic induced positive inotropy as well (Tang et al., 
2014).  
1.1.5.3. Inducible nitric oxide synthase (iNOS) 
Also known as type II NOS (NOS2), this isoform was identified in activated 
macrophages. From the first studies on it was evident, that this one differs from the others: 
it is Ca2+-independent (Knowles and Moncada, 1994). It is expressed in response to 
DOI:10.14753/SE.2016.1918
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inflammatory stimuli and the NO produced is important in protection against pathogens 
(Francis et al., 2010, p. -). 
1.1.6. NOS uncoupling: superoxide production 
NOS enzymatic activity depends on substrate and cofactor availability and on the 
rate of electron transfer (Thomas et al., 2008). Substrate or cofactor shortage result in 
uncoupling: electrons removed from NADPH and normally travelling through the 
enzyme are diverted from L-arginine to a molecular oxygen and superoxide is produced 
(Rochette et al., 2013; Roe and Ren, 2012). The resulting oxidative stress is accompanied 
by reduced NO bioavailability (Roe and Ren, 2012; Schäfer et al., 2004). 
Substrate (arginine) availability is influenced by competition with arginase, 
arginine uptake and methylation, and proteolysis to form symmetric and asymmetric 
dimethylarginine (SADMA and ADMA) (Rochette et al., 2013; Thomas et al., 2008).  
The critical regulator of NOS function is one of its cofactors, tetrahydrobiopterin 
(BH4). BH4 is either synthetized from GTP or regenerated from dihydrobiopterin (BH2) 
and its loss either by oxidation or reduced expression of the recycling enzyme 
dihydrofolate reductase (DHFR) is the most prominent cause of NOS uncoupling (Roe 
and Ren, 2012). Intracellular ROS will accelerate BH4 oxidation and in turn the reduced 
BH4 form will trigger further uncoupling. In addition paradox eNOS expression during 
oxidative stress further amplifies ROS production (Kim and Park, 2010; Rochette et al., 
2013). 
Oxidized BH4 and NOS uncoupling contribute e.g. to vascular dysfunction, 
hypertension, ischemia/reperfusion injury, diabetes and other cardiovascular diseases 
(Rochette et al., 2013). 
1.1.7. Endogenous NOS inhibitors 
Symmetric and asymmetric methyl-arginines - e.g.  ADMA, SDMA or NG-
monomethyl-L-arginine (L-NMMA) - inhibit NO synthesis in vivo by competing with L-
arginine at the active site of NO synthases (Leone et al., 1992). ADMA and SDMA are 
the major circulating forms of methylarginines in humans. (Leiper and Vallance, 1999).  
ADMA is continuously formed during intracellular protein turnover and its 
concentration is very sensitive to changes in expression or activity of its degrading 
enzymes, the dimethylarginine dimethyl-amino-hydrolases (DDAH) (Rochette et al., 
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2013). ROS increase may reduce DDAH activity and the resulting ADMA generation 
works as a second ROS-dependent, amplifying, feed-forward cellular loop that further 
stimulates ROS production (Rochette et al., 2013). Increasing bioactive NO availability 
can prevent ROS formation and is able to restore normal levels of ADMA (Carlström et 
al., 2011). 
SDMA does not have the same biological activity as ADMA and is not hydrolyzed 
by DDAH, but it can interrupt the transportation of arginine and other cationic amino 
acids as well (Huang et al., 2004; Leiper and Vallance, 1999).  
1.1.8. Nitric Oxide signaling 
Nitric oxide exerts its effects either via the cGMP dependent, or via the cGMP 
independent signaling pathway. Balance between these two pathways depends upon 
redox status that influences net NO chemistry and NO and cGMP synthetic capacity by 
NOS and soluble guanylate cyclase (sGC) (Kass et al., 2007b). 
1.1.8.1 cGMP dependent NO signaling 
1.1.8.1.1. Cyclic guanosine 3’,5’-monophosphate 
cGMP is a second messenger signaling molecule and is generated from guanosine 
triphosphate (GTP) by two distinct enzymes: the cytoplasmic heterodimeric 
haemoprotein sGC activated by NO and carbon monoxide (CO), and the transmembrane 
receptor particulate guanylate cyclases (pGC), activated upon binding of atrial and brain 
type natriuretic peptides (ANP and BNP), respectively (Burley et al., 2007; Garcia-
Dorado et al., 2009; Tsai and Kass, 2009). Since the discussed experimental work focuses 
on the role of the NO mediated signaling, the second, receptor linked GC class will not 
be discussed in detail. 
Direct targets of cGMP and participants of cGMP signaling are PKGs, cyclic 
nucleotide-gated ion channels (CNG), cGMP hydrolyzing phosphodiesterases (PDEs) 
and PDEs that contain allosteric cGMP binding sites. cGMP affinity among its targets 
varies and is modulated by phosphorylation or other modifications (Biel, 2009; Francis 
et al., 2010; Tsai and Kass, 2009). 
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1.1.8.1.2. Soluble guanylate cyclase (sGC) 
sGC consists of two homologous subunits and each subunit consists of a heme-
nitric oxide and oxygen binding (H-NOX), PAS (protein fold named for its association 
with the Per, ARNT, and Sim proteins), coiled-coil, and catalytic domain (Derbyshire and 
Marletta, 2012). Out of the two known active sGC isoforms (sGCα1β1 and sGCα2β1) 
sGCα1β1 is the principal isoform found in the heart and vasculature. NO mediated 
cardioprotection is lost without the α1 subunit and without the β1 subunit functional 
heterodimers are not formed (Derbyshire and Marletta, 2012; Nagasaka et al., 2008). 
NO binding to the soluble guanylate cyclase (sGC) can increases its activation 100-
200 fold (others mention 200-400 fold increase) (Francis et al., 2010; Tsai and Kass, 
2009). Two different states of sGC activation – basal and high activity – make sure that 
only an acute increase of NO levels, and the binding of a second NO to the enzyme is 
capable of fully activating the sGC (Cary et al., 2006; Tsai and Kass, 2009).  
sGC response to its ligands diminishes upon repeated exposure. S-nitrosation 
induced desensitization is rapid and has major influence on therapeutic applications 
(Derbyshire and Marletta, 2012).  
Since sGC is soluble, intracellular cGMP pool formation depends on the site of sGC 
activation and restriction of cGMP diffusion by PDE. This functional 
compartmentalization accounts for different intracellular effects (Burley et al., 2007; 
Francis et al., 2010). 
1.1.8.1.3. Protein kinase G (PKG) 
PKG was first identified in lobster tail muscle and so far two genes and families are 
known (PKGI and PKGII) (Burley et al., 2007). The members of the PKGI family 
(PKGIα and PKGIβ) are more commonly involved with NO mediated cGMP signaling. 
PKGIα transduces NOS / sGC signaling in the cardiovascular system and it requires one 
tenth of cGMP concentration for activation than does PKGIβ (Burley et al., 2007; Francis 
et al., 2010; Tsai and Kass, 2009). 
Oxidative processes can provide a NO / cGMP independent mechanism for PKGIα 
activation and auto-phosphorylation can change isozyme affinities and functions and 
further fine tune their regulatory role (Francis et al., 2010). 
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1.1.8.1.3.1. PKG regulation of calcium levels and signaling 
A modest NO availability will result in lower intracellular Ca2+ levels and interact 
with smooth muscle contraction, myocyte contractility, β-adrenergic response and 
attenuate cardiac hypertrophy (Francis et al., 2010). 
Modulation of L-type calcium channels (LTCC): LTCC phosphorylation is 
restricted to the caveolar microdomain by PDE5 and appears to be gender dependent. 
This regulatory pathway is believed to blunt contractile response to β-adrenergic 
stimulation, and attenuate calcineurin activation to prohibit NFAT (nuclear factor of 
activated T cells) translocation and hypertrophy (Tang et al., 2014). 
In addition direct phosphorylation of the Cav1.2 channel (Calcium channel, 
voltage-dependent, L type, alpha 1C subunit) also reduces Cav1.2. current and limits 
contractility (Yang et al., 2007).  
Troponin, regulating cardiac muscle contraction: troponin I phosphorylation 
reduces myofilament Ca2+ sensitivity (Layland et al., 2002). 
Phosphorylation of G-protein-activated phospholipase-Cβ3: phosphorylation will 
inhibit this enzyme and inhibit agonist stimulated intracellular calcium release (Xia et al., 
2001). 
Phosphorylation of inositol 1,4,5-trisphosphate (IP3) receptor-associated PKG 
substrate (IRAG): PKGIβ converts IRAG into an inhibitor of IP3-receptor activity and 
suppresses calcium release (Francis et al., 2010). 
Phospholamban phosphorylation: canceling its inhibition of the sarcoplasmic 
reticulum calcium/ATPase pump will increase calcium sequestration. Phospholamban 
phosphorylation can also occur via a cGMP independent pathway, namely PKA up-
regulation with S-nitrosylation (Francis et al., 2010; Tang et al., 2014). 
Ryanodine receptor (RyR) phosphorylation: phosphorylation will influence the 
function of the cardiac sarcoplasmic reticulum Ca2+ release channel (Burley et al., 2007; 
Zhang et al., 2005). 
1.1.8.1.3.2. PKGI-mediated inactivation of the Ras homolog gene family member A 
(RhoA) 
Rho kinase regulates actin cytoskeleton organization, stress fiber formation and 
vascular smooth muscle contraction and is inactivated and blocked by serine 
phosphorylation (Ellerbroek et al., 2003; Murthy et al., 2003; Surma et al., 2011).  RhoA 
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kinase inhibitors have demonstrated beneficial effects in the treatment of various 
cardiovascular diseases including arterial hypertension, atherosclerosis, I/R injuries, 
hypertrophic remodeling, cardiac dysfunction and heart failure (Surma et al., 2011). 
1.1.8.1.3.3. Gene regulation 
PKGI activity influences the expression of smooth muscle specific contractile 
proteins, proteins in the NO sGC signaling pathway, proteins regulating smooth muscle 
migration and differentiation, proteins influencing neuronal plasticity and learning and 
proteins in pathological conditions (Alzheimer’s and schizophrenia) (Francis et al., 2010).  
1.1.8.1.3.4. Phosphorylation of Vasodilator-Stimulated Phosphoprotein 
Vasodilator-Stimulated Phosphoprotein (VASP) is phosphorylated by both protein 
kinase G and protein kinase A (PKA). VASP signaling influences fibroblast motility, 
neutrophil migration, neuronal migration and endothelial function and could be 
potentiating metastasis formation (Krause et al., 2003). 
1.1.8.1.3.5. Phosphodiesterase 5 regulation 
PKGI mediated activation of the cGMP specific PDE5 is a powerful negative 
feedback on the NO / sGC / cGMP signaling pathway (Das et al., 2015a; Kass et al., 
2007b). 
1.1.8.1.3.6. Cytoprotection 
Cytoprotection was observed in myocytes, neurons and glia and epithelial cells.  
Opening of mitochondrial K+/ATP channels: cGMP can activate PKG localized at 
the cytosolic surface of the mitochondrial outer membrane. This may lead to the 
phosphorylation of a target protein that carries the cardio-protective signal to a protein 
kinase C isozyme (PKC-ε) residing in the intermembrane space of mitochondria and 
increase opening of mitochondrial K+/ATP channels (mitoKATP) (Costa et al., 2005; 
Francis et al., 2010). 
MitoKATP independent anti-apoptotic pathway: Activation of extracellular signal-
regulated kinase (ERK) and ERK dependent inactivation of glycogen synthase kinase 3β 
(GSK3β) by PKG phosphorylation also attenuates ischemia reperfusion injury and 
prevents cardio-myocyte apoptosis (Das et al., 2009; Francis et al., 2010). 
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Blockade of p38 mitogen-activated protein kinase is also reported to reduce cell 
damage, although these protective effects were not observed after sildenafil induced 
cGMP increase (Das et al., 2009; Francis et al., 2010).  
It was also suggested that the Bcl-2-associated death promoter (Bad) is likely to be 
an important downstream substrate of PKG-I, and its phosphorylation may contribute to 
the cGMP mediated survival in neural cells (Johlfs and Fiscus, 2010). 
1.1.8.1.3.7. Pro-apoptotic effects 
PKGI activity in colon cancer cells promotes apoptosis by phosphorylation and 
activation of the mitogen-activated protein kinase kinase (MEKK1), activation of the 
stress-activated protein/ERK kinase 1 (SEK1), and activation of the c-Jun NH2-terminal 
kinase 1 (JNK1) pathway (Deguchi et al., 2004; Soh et al., 2001). It also suppresses 
growth and promotes apoptosis in some endothelial cells and human colon tumor HT29 
cells (Francis et al., 2010). 
1.1.8.1.4. Cyclic nucleotide regulated ion channels 
Cyclic nucleotide regulated ion channels belong to the superfamily of voltage gated 
cation channels and are directly regulated by the binding of cAMP or cGMP. Channel 
activation is directly coupled to extracellular cation influx and plasma membrane 
depolarization. Two families can be distinguished: cyclic nucleotide gated (CNG) 
channels and hyperpolarization-activated cyclic nucleotide gated channels (HCN) (Biel, 
2009; Roubille and Tardif, 2013). CNG channels prefer cGMP over cAMP, while HCN 
channels have 10 fold higher affinity for cAMP (Biel, 2009; Podda and Grassi, 2013). 
 1.1.8.1.4.2. Cyclic nucleotide-gated channels (CNG):  
These channels play a key role in visual and olfactory signal transduction, but their 
role in other cell types remains unclear. CNG channels pass monovalent cations without 
discrimination. CNGs do not desensitize or inactivate after prolonged exposure to their 
ligands and they are influenced by divalent ion currents and several other factors (Biel, 
2009; Podda and Grassi, 2013). 
1.1.8.1.4.3. Hyperpolarization-activated cyclic nucleotide-gated ion channels (HCN):  
All four known HCN channel isoforms were identified in the myocardium and have 
a preference for K+. They activate on hyperpolarisation, which was the reason why the 
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current resulting from their activation was named funny (If). Regulation of these channels 
is complex, but modulation through their cyclic nucleotide binding domain region appears 
to be a common mechanism. Selective blockade of these channels is getting more and 
more attention in the treatment of heart failure patients (Roubille and Tardif, 2013). 
1.1.8.1.5. cGMP catabolism -  phosphodiesterases 
Phosphodiesterases are catabolic enzymes in charge of the fate of cGMPs and 
cAMPs. This 21 gene family of proteins was grouped into 11 different isozymes (Table 
2.) and 48 isoforms. Due to all these variants any organism is estimated to have more than 
fifty cGMP hydrolyzing enzymes at the same time. Cyclic nucleotide affinity varies, 
PDE5 / PDE6 / PDE9 are highly cGMP specific, PDE1 / PDE2 / PDE 11 have dual 
substrate affinity, and PDE3 / PDE 10 are cGMP sensitive but cAMP selective.  
Phosphodiesterases can be found in all tissues, but their distribution varies (Das et al., 
2015a; Francis et al., 2010; Kass et al., 2007b). cGMP-phosphodiesterases with known 
activity in the cardiovascular system are: 
 PDE1 is a Ca2+/calmodulin dependent enzyme,  
 PDE2, a cGMP-stimulated cAMP esterase that can also hydrolyze cGMP, 
 PDE3 although it is cAMP specific, it is inhibited by cGMP  
 PDE5 the first identified selective cGMP esterase 
 PDE9A could work as a “housekeeping” PDE to maintain low intracellular cGMP 
levels and controls nitric oxide independent cGMP and hypertrophic heart disease 
(Francis et al., 2010; Lee et al., 2015, p. 9). 
A large number of factors influence the catalytic function from PDEs, including 
processes that affect protein expression and breakdown, enzyme localization and 
substrate binding. For most PDEs their catalytic rate is high, thus absolute PDE 
concentration within a cell is low. In addition the Km value of different PDEs is also in a 
broad range of concentrations. This diversity together with enzyme and substrate 
compartmentalization enables phosphodiesterases to take part in a large variety of 
signaling processes (Francis et al., 2010). 
Under pathologic conditions PDE regulation contributes to the progression of 
several diseases. PDE3 down regulation influences heart failure progression, PDE1 
influences smooth muscle hypertrophy, sustained stimulation of PDE1 and PDE5 results 
in NO tolerance, PDE1 and PDE5 induction can be behind exacerbated hypertension and 
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PDE5 up-regulation is part of pulmonary hypertension and congestive heart failure (Kass 
et al., 2007b).  
1.1.8.1.5.1. PDE regulation 
Phosphodiesterases can undergo complex post-translational modifications. Among 
others, activation by Ca2+/calmodulin binding, or allosteric binding of cGMP may 
mediate PDE and protein interactions. (Das et al., 2015a). 
Allosteric cGMP binding to tandem regulatory GAF domains (its name derives 
from the first proteins it was found in:  cGMP-specific phosphodiesterases, adenylyl 
cyclases and FhlA) can act as an auto feedback mechanism (increasing catabolic activity 
for cGMP) or cross-regulation mechanism (activating catabolism of cAMP). Five of the 
known PDEs are equipped with a GAF domain: PDE2, PDE5, PDE6, PDE10 and PDE11. 
Binding affinities for the allosteric sites are much higher than for the catalytic sites, thus 
before reaching the catalytic site cGMP first induces a more active catalytic state and 
sustains an activated cGMP breakdown for a significant time. In addition ligand 
occupation of the catalytic site, phosphorylation of the regulatory domain, 
oxidation/reduction and other processes enhance GAF binding affinity. Allosteric binding 
of cGMP to a phosphodiesterase might as well serve as an intracellular storage and 
protection till later release (Francis et al., 2010; Kass et al., 2007b). 
Four of the PDEs (PDE1, PDE3, PDE4, PDE5) contain phosphorylation sites for 
various kinases and PDE phosphorylation by PKG is another mechanism to induce 
positive feedback. Phosphorylation of PDE5 by PKG may serve to increase its cGMP 
affinity and catalytic activity and represents an alternative mode of regulatory feedback 
inhibition to normalize cGMP levels (Das et al., 2015a; Kass et al., 2007b).  
Another type of modulation can happen at the catalytic site. In the case of PDE3 
catalytic site affinity is similar for both cyclic nucleotides, but a higher Vmax for cAMP 
confers specificity, while cGMP becomes a competitive inhibitor of PDE3 hydrolysis 
(Kass et al., 2007b). 
In the case of PDE1 an auto-inhibitory domain is known to maintain low activity in 
the absence of Ca2+, and neighboring calmodulin binding domains were found to 
reactivate the enzyme in the presence of Ca2+-Calmodulin (Kass et al., 2007b). 
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Table 2.  PDE isozymes, their specificity and selective inhibitors (Kass et al., 2007b). 
 
PDE 
isoenzyme 
Substrate Tissue expression 
Specific 
inhibitors 
1 Ca2+/calmodulin Heart, brain, lung, smooth muscle KS-505a IC 
86340 
2 dual specificity Adrenal gland, heart, lung, liver, 
platelets 
EHNA BAY 60-
7550 
3 cGMP inhibited, 
cAMP selective 
Heart, lung, liver, platelets, 
adipose tissue, inflammatory cells 
Cilostamide, 
enoxamone, 
milrinone 
4 cAMP specific Sertoli cells, kidney, brain, liver, 
lung,  
inflammatory cells 
Rolipram, 
roflumilast, 
cilomilast 
5 cGMP specific Lung, platelets, vascular smooth 
muscle, heart 
Sildenafil, 
tadalafil, 
vardenafil 
6 cGMP specific Photoreceptor Dipyridamole 
7 cAMP specific, 
high affinity 
Skeletal muscle, heart, kidney, 
brain, pancreas, T lymphocytes 
BRL-50481 
8 cAMP selective Testes, eye, liver, skeletal muscle, 
heart, kidney, ovary, brain, T 
lymphocytes 
None 
9 cGMP specific Kidney, liver, lung, brain, ?heart BAY 73-6691 
10 cGMP sensitive, 
cAMP selective 
Testes, brain None 
11 cGMP sensitive, 
dual specificity 
Skeletal muscle, prostate, kidney, 
liver, pituitary and salivary 
glands, testes 
None 
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1.1.8.1.5.2. PDE5 expression and regulation 
One PDE5 coding gene (PDE5A) and three gene expression variants are known. It 
is assumed that different promoters for the PDE5 isoforms allow physiologically relevant 
differential control of PDE5 gene expression and provide a long-term feedback 
mechanism for PDE5 activation (Kass et al., 2007a). High PDE5 expression rate in 
smooth muscle cells make determination of exact localization in vascularized tissues 
difficult. Intracellular localization is different among cellular compartments and seems to 
be at least partially dependent on the presence of eNOS (Kass et al., 2007a).  
PDE5 has two highly homologous GAF domains (A and B), but high affinity cGMP 
binding occurs only to the GAF-A domain. This domain is very similar to the PDE2 GAF-
B and PDE6 GAF A domains and stimulates substrate catalysis to its ten-fold. Although 
the enzyme is largely inactive in the absence of GAF ligand binding, under usual 
circumstances it is very likely to be occupied by cGMP and maintain full enzyme activity. 
Binding site phosphorylation either by PKG or PKA enhances cGMP binding affinity and 
stabilizes the increased catabolic activity. This is the way, by which sGC activators can 
promote a feed-forward enzyme activation and limit cGMP rise. The very same processes 
ensure easy and lasting binding of PDE5 inhibitors (Das et al., 2015a; Kass et al., 2007a). 
1.1.8.2. cGMP independent pathway 
NO directly regulates protein function via posttranslational modification of S-
nitrosylation (addition of a nitrosyl group to a free thiol on a cysteine residue of the target 
protein). S-nitrosylation is a redox based signal and it not only takes part in mammalian 
signaling, but can be used against the invasion of microbes or cancer cells as well (Stamler 
et al., 2001; Tang et al., 2014). 
Nitrosylation and nitrosative chemistry can lead to secondary oxidative 
modifications and production of reactive nitrogen species. These reactive nitrogen species 
can interact with reactive oxygen species, which can either impair its signaling and 
increase cytotoxicity (irreversibly oxidizing and nitrating proteins) or open up new 
signaling pathways. NO may as well promote cytotoxicity by mobilization of free iron or 
by the production of other oxidants, radicals and reactive aldehydes (Stamler et al., 2001). 
Recently it was proven that one of the main reperfusion injury quenching 
mechanisms of NO signaling is the reversible S-nitrosation of a mitochondrial protein 
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that will decelerate the mitochondrial electron transport chain (ETC) and inhibit extensive 
reactive oxygen species production during reperfusion (Schumacker, 2013).  
NOS1 produced NO takes advantage of the cGMP independent signaling pathway 
and modulates myocyte Ca2+ handling. Co-localization of NOS1 with the SR Ca2+ release 
channel, ryanodine receptor and xanthine oxidoreductase (XOR) on the sarcoplasmic 
reticulum enables their S-nitrosylation (Tang et al., 2014).  
1.2. Ischemia-reperfusion injury 
In case of an acute cardiac ischemic event, besides restoration of blood flow in 
ischemic areas, reduction of pre- and post-procedural damage is indispensable (Garcia-
Dorado et al., 2009). Revascularization of the culprit lesion is accompanied by ischemia-
reperfusion (I/R) injury, which is responsible for about 40-50% percent of myocardial 
damage suffered (Figure 2.) (Yellon and Hausenloy, 2007). 
Ischemia reperfusion can cause four types of cardiac dysfunction: the mechanical 
dysfunction known as myocardial stunning, the disruption of microvascular circulation  
in the reperfused tissue (“no reflow”), reperfusion arrhythmias and lethal reperfusion 
injury (Yellon and Hausenloy, 2007). 
During lethal reperfusion injury myocardial cell death occurs mainly as necrosis: 
histological analysis of reperfused infarcts showed composed areas of contraction band 
necrosis and ultrastructure showed sarcolemmal rupture and massive calcium deposits. 
Contraction band necrosis, when myocytes show characteristic disruption of their 
architecture and disorganization of their sarcomeres, is usually referred to as 
hypercontraction or round-up (Garcia-Dorado et al., 2009). 
1.2.1. Biochemical and metabolic changes during ischemia reperfusion 
Ischemia-reperfusion subjects the myocardium to several biochemical and 
metabolic changes. During prolonged ischemia intra- and extracellular acidosis, energy 
depletion, Na+ and Ca2+ overload and hyper-osmolality develops.  Upon reperfusion 
mitochondrial re-energization, generation of reactive oxygen species (ROS), intracellular 
Ca2+ overload, rapid restoration of physiologic pH, and inflammation interact and induce 
cell death.  
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1.2.1.1. The ischemic cascade 
A switch from aerobic to anaerobic metabolism result in lactic acid accumulation. 
The resulting acidosis together with the fall in ATP concentration and consequent failure 
of ATP dependent processes triggers an uncontrolled rise in intracellular ion levels. ROS 
production increases and disrupts sarcolemmal and mitochondrial function, facilitating 
cell death (McAlindon et al., 2015). 
1.2.1.2. pH normalization 
The rapid wash-out of lactic acid and the activation of the sodium-hydrogen 
exchanger and the sodium–bicarbonate symporter results in quick pH restoration and may 
lead to potassium ion overload, which in turn results in a reversed Na+/Ca2+ exchanger 
activity and additional calcium influx (Bond et al., 1991; Garcia-Dorado et al., 2009; 
Yellon and Hausenloy, 2007). After restoration of pH mitochondrial ROS formation is 
initiated and mitochondrial PTP (Permeability Transition Pore) channels activate (Kim et 
al., 2006).  
1.2.1.3. ROS generation 
Xanthine oxidase (XO), the mitochondrial electron transport chain, NADPH 
oxidase (Nox) and NOS uncoupling are the known sources of ROS (Zweier and Talukder, 
2006). Nox is thought to be the major source of O2
- and H2O2 in the heart and it is 
upregulated during ischemia reperfusion injury. Nox is a double edged sword as minimal 
activity is needed to maintain peroxisome proliferator-activated receptor alpha (PPARα) 
and hypoxia-inducible factor-1α (HIF-1α) conferred cardioprotection. The consumption 
of NAD(P)+/NAD(P)H by Nox is an alternative regulatory mechanism of redox state and 
thus mitochondrial electron transport (Chen and Zweier, 2014; Matsushima et al., 2014). 
ROS induce mitochondrial PTP opening, attract neutrophils, mediate sarcoplasmic 
reticulum dysfunction and contribute to intracellular Ca2+ overload, damage the cell 
membrane by lipid peroxidation, induce enzyme denaturation, and cause direct oxidative 
damage to DNA.(Yellon and Hausenloy, 2007; Zweier and Talukder, 2006).  
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1.2.1.4. Calcium oscillation 
Parallel restoration of respiration to pH normalization allows mitochondrial 
repolarization and ATP synthesis. This favors calcium uptake into the mitochondria and 
sarcoplasmic reticulum and despite the higher calcium influx cytosolic calcium levels 
fall. Increased calcium concentration in the sarcoplasmic reticulum interacts with the 
ryanodine receptor and calcium oscillations (release/reuptake) propagate across the cell 
(Garcia-Dorado et al., 2009). This can lead to hyper-contraction and disorganization of 
the cell structure, but to damage the sarcolemmal membrane the proteolysis of the 
subsarcolemmal cytoskeleton by calpains (calcium dependent and calcium activated 
proteases) is necessary as well(Garcia-Dorado et al., 2009; Inserte et al., 2004). 
1.2.2.5. Targeting the mitochondria   
The opening of the mitochondrial PTP channel during the first few minutes of 
reperfusion collapses mitochondrial membrane potential and uncouples oxidative 
phosphorylation: ATP depletion and cell death occur (Yellon and Hausenloy, 2007). 
Direct or PI3K / AKT / NOS / GC mediated PKG and PKC activation will induce 
the mitochondrial ATP-dependent K channel (KATP) and ROS formation resulting in p38 
Figure 2. Components of final myocardial injury. This scheme taken from Yellon and 
Hausenloy depicts the contribution of both ischemia and reperfusion injury to final 
myocardial injury.52 
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mitogen-activated kinase and PKC activation and priming of mitochondrial PTP for 
opening (Heusch et al., 2008). 
Two endogenous cardioprotective pathways, the Reperfusion Injury Salvage 
Kinase (RISK) and the Survival Activating Factor Enhancement (SAFE) pathways, are 
known to inhibit mitochondrial PTP, activate mitochondrial connexin-43 channels and 
open mitochondrial ATP dependent potassium channels (Hausenloy et al., 2013). 
Activation of sarcolemmal G-protein–coupled receptors or of receptors for growth 
factors result in activation of the RISK program. The RISK pathway includes the pro-
survival kinase cascades MEK1/2-Erk1/2 and involves PI3K/Akt/NO signaling, p70S6K 
(extracellular regulated kinase system with downstream p70 ribosomal protein S6 kinase) 
and GSK3β (glycogen synthase kinase 3β) activation (Heusch et al., 2008). 
The SAFE pathway is made up by the TNF-α (tumor necrosis factor-α) receptor 
and STAT3 (Hausenloy et al., 2013). After activation of gp130 (sarcolemmal 
glycoprotein 130) receptors or TNF α receptors, the janus-activated kinase (JAK) and 
signal transducer and activator of transcription (STAT) pathway is activated with 
projection to the nucleus and possibly to mitochondria (Heusch et al., 2008). As an 
upstream regulator of TNF-α NO influences this pathway as well (Thielmann et al., 2002). 
1.2.2.6. Neutrophil involvement in lethal myocardial reperfusion injury 
Neutrophil response to reperfusion is triggered by cytokines, the complement 
system, ROS and various lipid mediators. Compared to ischemia only, reperfusion 
accelerates neutrophil infiltration and focuses their accumulation in the sub-endocardium 
(Chatelain et al., 1987; Vinten-Johansen, 2004). Initial, rapid neutrophil adhesion to the 
endothelium is accompanied by a reduced endothelial function (Vinten-Johansen, 2004). 
For the first 6 hours cells stay in the intravascular space and after the 6th hour start to 
migrate to the parenchyma (Zhao et al., 2000). 
Neutrophils can form aggregates with platelets, plug capillaries and mechanically 
stop blood flow (Engler et al., 1983; Hataishi et al., 2006; Wong et al., 2013). Together 
with platelets and damaged endothelial cells they release vasoconstrictors and contribute 
microvascular constriction (Niccoli et al., 2009; Wong et al., 2013). Both processes 
contribute actively to the “No reflow” phenomenon. 
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Neutrophils can induce endothelial dysfunction and by impairing NO generation 
contract arteries (Vinten-Johansen, 2004). Endothelial dysfunction is nearly restored after 
72 hours following reperfusion (Zhao et al., 2000). 
Neutrophils release more than 20 different enzymes which primary target is the 
extracellular matrix. While these enzymes have a relatively long half-life and catalyze 
specific reactions, ROS produced by neutrophil is responsible for fast, aspecific and 
widespread destruction (Vinten-Johansen, 2004). 
The reduction of neutrophil infiltration is associated with reduced infarct size and 
attenuated adverse cardiac remodeling while after the 3-7th post-ischemic day this could 
possibly assist repair mechanisms (Carbone et al., 2013; Huang et al., 2007). Limitation 
of neutrophil recruitment is one of main cardio-protective mechanisms attributed to 
inhaled NO (Hataishi et al., 2006). 
1.2.2.7. NOS uncoupling  
Nitric oxide signaling, previously described in detail, can interact with lethal 
myocardial injury on several levels. Ischemia reperfusion will induce NOS uncoupling, 
reduce NO bioavailability and produce ROS. Most probably due to the decreased GC 
activity under acidic conditions cGMP levels will drop and the activity of the cGMP 
dependent pathway will decrease. The very same pathway that directly effects 
contractility, calcium handling, activates protective cascades, regulates mitochondrial 
PTP, inhibits platelet activation, reduces endothelial adhesion protein expression, 
increases endothelial permeability and induces vasorelaxation (Garcia-Dorado et al., 
2009). In addition the cGMP independent pathway reversibly S-nitrosylates one of the 
electron transport chain components (a subunit of mitochondrial complex I) and thus 
slows it down (Schumacker, 2013). A study with selective sGC/NO/cGMP signaling 
inhibition even suggested, that nitrosylation might play a more important role in 
cardioprotection (Sun et al., 2013). 
1.3. Modulation of the nitric oxide mediated signaling pathway – 
therapeutic applications 
Nitric oxide generating drugs have long been used by physicians and are still in the 
first line of medical therapies (e.g. nitro-glycerine) while other fields of use are severely 
DOI:10.14753/SE.2016.1918
 32 
 
limited by systemic vasodilatation. To avoid this unwanted side effect novel NO donor 
compounds and agents to sensitize or to directly activate NO signaling were developed 
and are being tested (Bryan and Loscalzo, 2011). 
1.3.1 Inhaled nitric oxide 
Before 1990 NO was considered poison. Zapol  and Frostel in their publication from 
1991 proved that inhalation of low concentrations of nitric oxide (up to 80 ppm) is safe 
and effectively relaxes pulmonary vascular smooth muscle, without systemic 
vasodilatation (Frostell et al., 1991). Short gas transit time and low concentrations ensure 
that during inhaled NO administration NO2 concentrations remain under 5 ppm and 
measuring met-hemoglobin levels establishes adequate therapy-monitoring (Bhatraju et 
al., 2015; Frostell et al., 1991) (Figure 3.).  
1.3.1.1. Taking advantage of pulmonary effects 
Nitric oxide/oxygen blends are used in critical care to promote capillary and 
pulmonary dilation to treat a variety of diseases. These are often last-resort gas mixtures 
before the use of extracorporeal membrane oxygenation (ECMO) (Bryan and Loscalzo, 
2011). 
Nitric oxide inhalation is an approved therapy for persistent pulmonary 
hypertension of the new-born (PPHN), for chronic obstructive pulmonary disease, in 
patients with pulmonary hypertension and undergoing cardiac surgery, in patients 
undergoing left ventricular assist device (LVAD) implantation in patients with right 
ventricular infarction or pulmonary embolism (Adhikari et al., 2014; Argenziano et al., 
1998; Bhatraju et al., 2015; Bloch et al., 2007; Bryan and Loscalzo, 2011). 
 1.3.1.2. Extrapulmonary effects of inhaled NO 
Identifying inhaled NO related platelet inhibition broke the paradigm that its effects 
are limited to the lungs (Frostell et al., 1991; Högman et al., 1993). A number of extra-
pulmonary effects were described ranging from reducing neointima formation and 
inflammatory modulation in malaria to reduction of ischemia-reperfusion injury and 
protection of the central nervous system. Cardiovascular applications were studied and 
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verified as well (Bergmark et al., 2012; Bryan and Loscalzo, 2011; Charriaut-Marlangue 
et al., 2013; Mathru et al., 2007; Phillips et al., 2009). 
1.3.1.2.3. Cardiopulmonary resuscitation 
In mice it was proven that NO inhalation has protective effects on the outcomes of 
cardiopulmonary resuscitation. The neuro-protective effects largely depend on sGC-
mediated mechanisms, although the role of sGC independent and NO metabolite 
mediated arteriole dilatation could not be excluded (Ichinose, 2013). 
1.3.1.2.6. Myocardial ischemia-reperfusion injury:  
Several experiments were conducted to prove the effectiveness of inhaled NO 
therapy in attenuating myocardial reperfusion injury (Bhatraju et al., 2015; Bloch et al., 
2007). Pre-clinical studies agree on the infarct size limitative and cardiac function 
preserving effects of this therapy (Hataishi et al., 2006; Liu et al., 2007; Nagasaka et al., 
2008; Neye et al., 2012). A larger scale international, randomized, double-blind clinical 
study was conducted recently, the NOMI trial – as this work strongly connects to it - will 
be discussed separately.   
1.3.1.3. Theories behind extrapulmonary effects 
Although therapeutic systemic applications are known and were proven by several 
groups, the question remains: how can NO, with its short half-life in biological fluids, 
reach the periphery and elicit its effects?  
First extrapulmonary effects were attributed to changes in platelet and leukocyte 
function and only after discarding this turned the scientific interest towards stable NO 
metabolites. Nitric oxide can react with heme in hemoglobin forming nitrosyl hemoglobin 
and can nitrosylate the cysteine in the hemoglobin to form SNO-hemoglobin. This 
reaction will occur in the presence of high oxygen concentrations and NO will be released 
under low oxygen concentrations (Bryan and Loscalzo, 2011; McMahon and Doctor, 
2006). 
Nitrite and nitrate are also candidates for the cardio protective effects, as they could 
be major stable reservoirs of NO. Nitrite was proven to dramatically reduce infarct size 
in a canine model, and was suggested as potent adjunctive therapy in myocardial 
reperfusion injury (Gonzalez et al., 2008). 
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Nitric oxide also reacts with a variety of plasma components - proteins, peptides 
and lipids – and forms intravascular agents capable of endocrine vasodilatation: S-
nitrosthiols, N-nitrosamines, iron-nitrosyls and nitrated lipids (Bryan and Loscalzo, 2011; 
Gonzalez et al., 2008).  
1.3.2. Other inhaled drugs to modify NO signaling 
Inhalation is an effective way to administer various NO donor agents: nitroglycerin 
relieves angina pectoris, and sodium nitroprusside may improve oxygenisation in hypoxic 
neonates and reduce PVP and PVR in children with congenital heart disease (CHD). O-
nitrosoethanol (an S-nitrosothiol) was reported to improve oxygenation and systemic 
hemodynamics in hypoxemic newborns. Nitrite can also be converted to NO by a variety 
of enzymes (e.g. hemoglobin and xanthine oxidoreductase) (Bryan and Loscalzo, 2011). 
PDE5 inhibitors (e.g. sildenafil) and sGC stimulators potentiate the pulmonary 
vasodilator effects of NO (Evgenov et al., 2007; Ichinose et al., 2001). 
1.3.3. Phosphodiesterase 5 inhibition 
After the commercial success of Viagra it took almost a decade for PDE5 inhibition 
to make its comeback into more direct cardiovascular applications. The recognition that 
it is responsible for ~22-43% of cytosolic cGMP hydrolytic activity and that under 
Figure 3.  Schematic image of an alveolar capillary unit. NO dilates pulmonary 
arterioles and reduces pulmonary artery pressure (PAP). Inhaled NO does not dilate 
systemic arterioles or alter systemic arterial pressure (SAP) under normal conditions.6 
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pathologic conditions its expression is upregulated 2 to 6 fold opened new frontiers in 
cardiovascular research (Das et al., 2015a; Kass et al., 2007a). 
PDE5 inhibitors provide protection from ischemia-reperfusion injury and preserve 
left ventricular function, improve survival rate, reduce apoptosis in the infarct border zone 
and reduce heart failure progression (Das et al., 2015a; Salloum et al., 2008). Extracardial 
uses include dampening of systemic inflammation in diabetic patients, protection of stem 
cells from I/R injury, reducing I/R injury in skin island flaps, neuroprotection and 
anticancer effects (Das et al., 2015a; Gulati and Singh, 2014a, 2014b; Kayiran et al., 
2013). The most studied compounds are sildenafil, vardenafil and tadalafil. (Table 3.) 
PDE5 inhibitors interact with gaso-transmitters (e.g. NO and H2S), as it was seen 
after blocking the H2S producing enzyme: cardio-protective effects of tadalafil were 
abolished (Das et al., 2015a). 
 
Table 3. PDE5 inhibitors for cardiovascular use. Data on metabolism and 
pharmacokinetics in humans was taken from http://toxnet.nlm.nih.gov/ (US National 
Library of Medicine, n.d.). 
 
 Sildenafil citrate Vardenafil Tadalafil 
Molecular 
structure(Kukreja 
et al., 2004) 
   
Bioavailability 40% 14.5% N/A 
Tmax 1h 40min 2h 
T1/2 4h 4h 17.5h 
Metabolism CYP3A4, CYP2C9  CYP3A4, CYP3A5 
CYP2C 
CYP3A4 
Active metabolite Yes  
(20% of activity) 
Yes  
(7% of activity) 
No 
Elimination Feces Feces 91-95%,  
urine 2-6% 
Feces 61%,  
urine 36% 
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Recently some researchers questioned the role of PDE5 in the cardiac cGMP-PKG 
signaling, as they failed to detect PDE5 in tissue lysates (mouse, canine and human) and 
to increase hypertrophy by creating cardiac specific PDE5 knock out animals (Degen et 
al., 2015; Lukowski et al., 2010). 
1.3.3.1. Protection against ischemia-reperfusion injury  
Both sildenafil and vardenafil were effective not only when administered prior 
ischemia, but when given at the time of reperfusion as well. Preclinical data on I/R injury 
and ischemic cardiomyopathy showed beneficial effects of PDE5 inhibition on collagen 
deposition and verified functional therapeutic benefits with both echocardiography and 
invasive pressure volume analysis of the left ventricle (Pokreisz et al., 2009; Salloum et 
al., 2014; Sesti et al., 2007). 
To exert cardio-protection these agents influence mitochondrial KATP and 
mitochondrial Ca2+ channels, and the cGMP/PKG pathway also confers protection. 
Beside PKG activation enhanced eNOS and iNOS expression and an increased Bcl-2/Bax 
ratio also mediate cardioprotection (Chau et al., 2011; Salloum et al., 2014, 2008). 
Tadalafil also attenuated ischemia-reperfusion injury via PKG dependent generation of 
hydrogen sulfide (Salloum et al., 2009). In vitro studies proved that these anti-necrotic 
and apoptotic effects are independent from the vasculature and hemodynamics (Das et 
al., 2015a). 
Myocardial infarct size reduction was also observed in diabetic models, which are 
known to be refractory to some cardio-protective modalities. Chronic tadalafil treatment 
improves cardiac function, NO bioavailability and also promotes antioxidant like effects 
(suppresses ROS production, NADPH oxidase activity, lipid peroxidation and oxidizes 
glutathione) (Das et al., 2015a; Koka et al., 2014, 2013). 
1.3.3.2. Protection against ischemic and doxorubicin induced cardiomyopathy 
Sildenafil and tadalafil attenuated ischemic cardiomyopathy and slowed down heart 
failure progression. Beneficial effects are associated among others with the activation of 
Rho kinases and the production of hydrogen sulfide (Das et al., 2015a; Salloum et al., 
2014, 2009). 
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Both sildenafil and tadalafil improved left ventricular function in doxorubicin 
induced cardiomyopathy, without interfering with the chemotherapeutic benefits (Das et 
al., 2015a). 
1.3.3.4. Protection against cardiac hypertrophy:  
PDE5 inhibition restores cGMP signaling and blunts the Akt-PI3K, the calcinerurin 
/ NFAT and ERK 1 / 2 signaling pathways, both known to contribute to cardiac 
hypertrophy (Bueno et al., 2000; Molkentin et al., 1998; Takimoto et al., 2005). Sildenafil 
treatment is known to suppress pressure overload induced cardiac hypertrophy and 
recently it was shown that its cardioprotective effect is estrogen dependent (Sasaki et al., 
2014; Takimoto et al., 2005). Marked PDE5 expression was found in the left ventricle of 
patients with end-stage ischemic or dilated cardiomyopathy and blunted cGMP response 
in PDE5 overexpressing animals lead a more marked impairment of LV systolic and 
diastolic function (Pokreisz et al., 2009).  
 After the first unsuccessful trials preclinical data were reevaluated and the 
presence of PDE5 in cardiomyocytes questioned. These authors link the anti-hypertrophic 
effects to myofibroblasts and other cell types. In addition it was suggested that PDE5 
inhibitor mediated cardioprotective effects are linked to the inhibition of PDE1C by the 
large compound concentrations used in the preclinical studies (Lukowski et al., 2014). 
1.3.4. sGC stimulators and activators 
 Nitric oxide is not the only ligand capable to induce sGC activation. 
Nitrosoalkanes, alkyl isocyanides and CO can bind to the sGC heme, albeit they only 
weakly activate it (Derbyshire and Marletta, 2012; Priviero and Webb, 2010). The search 
for sGC modulating drugs and resulted in identification of activators and stimulators of 
sGC (Derbyshire and Marletta, 2012). 
1.3.4.1 sGC activators 
Activators act independent of NO and of the prosthetic heme group as well. The 
most well-known activator of sGC is Cinaciguat (BAY 58-2667) and can activate 
regulatory sites on both α- and β- subunits of the enzyme. During oxidative stress, when 
the enzyme is exposed to superoxide and peroxynitrite, elevation in the oxidation induced 
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heme-free sGC levels increases Cinaciguat potency (Mitrovic et al., 2011; Schmidt et al., 
2009). In addition this compound also stabilizes sGC, prolongs its half-life and can 
reverse the oxidation induced enzyme degradation (Derbyshire and Marletta, 2012; 
Schmidt et al., 2009). A number of clinical studies investigated Cinaciguat in heart failure 
and found beneficial effects on cardiac output and pulmonary pressure with accompanied 
hypotension (Mitrovic et al., 2011). 
Another very promising agent is Ataciguat, which has already proven beneficial 
effects in post-MI heart failure and improved chronic heart failure without lowering blood 
pressure (Fraccarollo et al., 2014). 
1.3.4.2. sGC stimulators 
The sGC stimulators are heme dependent and potentiate the effects of NO and 
CO. YC-1 was the first stimulating agent to be described, but was less potent than NO 
donors in inducing vasorelaxation. The search for more potent drugs led to the synthesis 
of pyrazolopyridinylpyrimidines derivatives: BAY 41-2272, BAY 41-8543, AND BAY 
63-2521 (Priviero and Webb, 2010). Clinical studies evaluating Riociguat (BAY 63-
2521, trade name Adempas) in pulmonary hypertension and heart failure revealed 
positive effects and good tolerability. This is the first of its class to get FDA approval 
(chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension) 
(Derbyshire and Marletta, 2012; Mitrovic et al., 2011). 
Under pathologic conditions with increased oxidative stress sGC oxidation and 
degradation diminishes the effect of stimulator molecules (Priviero and Webb, 2010). 
1.4. The role of NOS in physical conditioning 
1.4.1. Structural changes in the left and right ventricles among athletes 
Intensive physical conditioning is associated with development of enlarged 
myocardial mass, resulting in both left- and right ventricular (LV, RV respectively) 
hypertrophy and increased stroke volumes at rest. This phenomenon is usually referred to 
as athlete’s heart (Prior and Gerche, 2012; Scharf et al., 2010; Scharhag et al., 2002). 
Despite different workload between sport disciplines (strength, endurance and combined 
strength and endurance) LV mass increases in a similar fashion in all athletes (Prior and 
Gerche, 2012). (Although data are somewhat conflicting (Baggish and Wood, 2011).) 
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However in endurance athletes the load on the right ventricle can be disproportionately 
higher than the load on the left ventricle (LA Gerche et al., 2011; Perseghin et al., 2007). 
Little is known about athletes engaged in static exercise, although one study reported RV 
volume increase in sprinters (Prior and Gerche, 2012).  
1.4.2. Functional changes in the left and right ventricles among athletes 
Compared to pathological remodeling athletes heart is known to have preserved or 
even enhanced left ventricular function. When comparing ejection fraction, athletes have 
values close to general public (with the exception of endurance athletes with dilated 
hearts: their ejection fraction can be as low as ~40%), suggesting that less vigorous 
contractions are sufficient to maintain circulation. There is a shift in the focus of interest 
towards strain and strain rate measurements to assess both systolic and diastolic function. 
These studies on diastolic filling suggested that cardiac remodeling in athletes heart is not 
associated with diastolic dysfunction and that athletes may be able to utilize the Frank-
Starling mechanism more effectively (Baggish and Wood, 2011; Prior and Gerche, 2012). 
As part of a balanced, biventricular enlargement right ventricular function shows 
similar changes: ejection fraction is comparable with untrained individuals, however RV 
deformation is reduced. Studying RV function under exercise demands could be the key 
to unveil more characteristic differences in athlete’s heart (Baggish and Wood, 2011; 
Prior and Gerche, 2012). 
Rigorous training also results in electrical remodeling and distinct ECG changes. 
Sinus bradycardia, first degree AV block, incomplete RBBB, early repolarization and 
voltage criteria for LVH may be considered normal, while other abnormalities such as T 
wave inversion, complete bundle branch blocks, and left atrial enlargement on ECG are 
not regarded as training related changes and further evaluation is recommended (Corrado 
et al., 2010; Prior and Gerche, 2012). 
Positive correlation was observed with myocardial mass of both ventricles and with 
maximal oxygen uptake - a marker of maximal work capacity (Scharhag et al., 2002). 
Recently total heart volume was introduced as an independent predictor of maximal work 
capacity in both athletes and non-athletic individuals (Steding et al., 2010). 
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1.4.3. Mechanisms of athletic cardiac remodelling 
In athlete’s heart myocardial mass increases with minimal extracellular expansion 
and is mainly mediated by trophic hormones. Insulin-like growth factor 1 (IGF1) 
elevation positively correlates with LV mass index and LV end diastolic dimension index 
(Weeks and McMullen, 2011). IGF1 receptor stimulation leads to phosphoinositide 3-
kinase p110α [PI3K(p110α)] activation. PI3K(p110α) is a lipid kinase that is responsible 
for phosphatidylinositol 3,4,5-trisphosphate (PIP3) formation. PIP3 acts as a second 
messenger to cause downstream signaling events, such as phosphorylation and activation 
of Akt, a serine/threonine kinase that plays a central role in cardiac myocyte growth and 
survival via its effects on protein synthesis and apoptosis. PI3K(p110α) and Akt are 
critical for normal heart growth, and growth in response to exercise training (Ellison et 
al., 2012; Weeks and McMullen, 2011).  Myocardial IGF-1 overexpression also increases 
the survival and number of endogenous cardiac stem and progenitor cells (eCSC) and 
prevents myocyte attrition during ageing (Ellison et al., 2012).  
Exercise training is one of the most powerful regulators of vascular eNOS activity 
(Indolfi et al., 2002). eNOS signaling is involved with length-dependent increase in 
cardiac contraction force, regulates mobilization, recruitment, migration and 
differentiation of cardiac and vascular progenitor cells and at least in part induces c-kitpos 
eCSC activation and ensuing vascular/endothelial differentiation, as well as homing of 
circulating bone marrow-derived progenitor cells and their differentiation into vascular 
lineages (Ellison et al., 2012). 
Modulation of SERCA2a and phospholamban activity explain faster Ca2+ transient 
decay rate after exercise training. Akt and NOS signaling (as discussed in section 
1.1.8.1.3.1.) have also been shown to modulate LTCC stability and phospholamban-
SERCA interaction, which could influence cardiomyocyte Ca2+ entry, handling and 
contractility (Ellison et al., 2012). 
1.4.4. Possible interactions of NO and NOS3 polymorphisms with athletic 
cardiac remodelling   
Nitric oxide (NO) influences exercise performance through effects on skeletal 
muscles and cardiac function as well (Matter et al., 1999; Stamler and Meissner, 2001). 
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Genetic variants of the main cardiac NO source, the endothelial NO synthase may have 
an impact on NO bioavailability and NOS signaling. 
 The 894 G/T variant of the NOS3 gene predicts a Glu to Asp amino acid 
substitution at codon 298 in the mature protein and results in decreased NO production in 
vitro (Tesauro et al., 2000). This genetic variant also associates with sport-related cardiac 
adaptation, since non-athletic carriers of the Asp allelic variant developed higher stroke 
volumes and heart rates during sub-maximal exercise following a long-term endurance 
training (Hand et al., 2006). The genotype distribution of this variant shows no difference 
between elite endurance athletes and sedentary controls (Wolfarth et al., 2008). However, 
elite male triathletes of the South African Ironman Triathlon, with the NOS 298 Glu/Glu 
genotype had better athletic performance with significantly lower finishing times than 
individuals carrying the Asp allelic variant (Saunders et al., 2006). 
1.4.5 Exercise induced right ventricular dysfunction 
Compensatory mechanisms – reduction of vascular resistance and increase of 
compliance – are limited in the lesser circulation (La Gerche et al., 2014). Extreme 
exercise will result in a disproportionate load on the right ventricle and may promote pro-
arrhythmic remodeling in athletes. This remodeling, termed by some as exercise induced 
arrhythmogenic right ventricular cardiomyopathy, might be the underlying cause for a 
higher risk of major arrhythmias in endurance athletes (Gerche et al., 2012; Heidbüchel 
et al., 2003; Heidbüchel and La Gerche, 2012; LA Gerche et al., 2011; La Gerche et al., 
2010).  
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2. Objective: to identify new aspects of NOS signaling 
under physiologic and pathophysiologic conditions 
Nitric oxide signaling is a fundamental part of cardiovascular regulation in both 
physiologic and pathophysiologic processes. My work addresses two distinct and special 
aspects of NO mediated cardioprotection: reduction of ischemia reperfusion injury and 
adverse ischemic remodelling, and athletic adaptation of the human heart. 
2.1 Murine experiment on potentiation of NO derived cardioprotection  
A murine ischemia-reperfusion study was conducted to assess the potential benefit of 
concomitant cGMP generation using inhaled NO (iNO) and inhibition of its degradation 
by PDE5 inhibition using tadalafil (TAD). My objectives were to: 
 Establish a reproducible murine I/R model. 
 Evaluate the effect of iNO and TAD therapies on functional and structural changes 
after ischemia reperfusion injury. 
2.2. Clinical study on the role of NOS3 polymorphisms in physiologic 
adaptation in elite athletes 
Effects of genetically determined changes of NO bioavailability on exercise induced 
cardiac adaptation were studied in elite athletes with single gene approach. My objectives 
were: 
 To establish a DNA extraction and single nucleotide polymorphism (SNP) 
analysis protocol for local screening programs. 
 To assess the influence of the Glu298Asp polymorphism in NOS3 gene on athletic 
adaptation 
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3. Methods 
3.1. Murine experiment on potentiation of the NO mediated 
cardioprotection with PDE5 inhibition 
3.1.1. Drugs used in the experiments 
Tadalafil (commercial name Cialis): tadalafil activity is unaffected by food and has 
a relatively short time to onset of action (16 to 17 minutes). Maximal plasma 
concentration is reached within 2.0 hours and it has an elimination half-life of 17.5 hours. 
Tadalafil is a highly selective inhibitor of PDE with 10 000-fold selectivity for PDE-5 
over PDE-1 to PDE-4 and approximately 700-fold selectivity for PDE-5 over PDE-6 
(Salloum et al., 2009). As it is not water soluble, a 30% cyclodextrane solution was used 
as medium. Solution concentration was 0.4ug/ul. 
Inhaled nitric oxide (iNO): The INOVent gas delivery system is an older type 
clinical equipment currently applied in the experimental animal laboratory at the Catholic 
University Leuven for nitric oxide gas delivery to intubated animals in range from mice 
to pigs via a dedicated ventilator. Two cylinders containing nitric oxide balanced in 
nitrogen are attached to the delivery device with gas-tight specific tubing with US-type 
connectors. Gas content is 10L / cylinder (Product code [according to manufacturer]: 
660.011.01, Pressure: 155 bar [corresponds to 1535 L of gas at 1 bar pressure], 
manufacturer: Ino Therapeutics LLC, Hampton, NJ 08827, United States) 
3.1.2. Induction of I/R and experimental design  
Animal experiments were approved by the Ethics Committee for Animal 
Experimentation (KU Leuven) and were performed in accordance with the Guide for Care 
and Use of Laboratory Animals (NIH). C57Bl6J mice (Charles River Laboratories, 
Chatillon-sur-Chalaronne, France) were housed in temperature and light-cycle controlled 
facilities and had access to rodent chow and water ad libitum. Age matched (8-10 weeks 
old), adult, male mice (20-35g) were anesthetized using sodium pentobarbital (40-60 
mg/kg, IP Nembutal, Sanofi Synthelabo, Belgium) supplemented with morphine 
hydrochloride (0.5-1 mg/kg, SC, Stellorphine, Sterop Laboratories, Brussels, Belgium) 
and ventilated with room air using 250 µL tidal volume at 150 strokes/min 
(Miniventilator, Hugo Sachs Elektronik, Germany). Depth of anesthesia was controlled 
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by pedal withdrawal reflex during the entire procedure. Following a left sided 
thoracotomy, ischemia was induced by 60 min transient ligation of the left anterior 
descending artery (LAD) using 7-0 silk suture (Ethicon, Johnson&Johnson, Brussels, 
Belgium). After one hour, the ligation was released and blood flow restored. Wounds 
were closed using 6-0 Ticron suture (Sherwood Davis&Geck, Quebeck, Canada) and 
animals were allowed to recover in temperature-controlled cages. Post-operative pain 
suppression (buprenorphine, 100 µg/kg IP, Temgesic, Schering-Plough, Hull, UK) was 
administered during the first two post-operative days.  
Mice were randomized after I/R into four treatment groups and followed for four 
weeks (4w): untreated CON (CON, n4w=17), inhaled nitric oxide (iNO, n4w=17), 
tadalafil (TAD, n4w=16) and combination treatment with iNO and TAD (iNO+TAD, 
Figure 4 Experimental design. Four different study groups were established: ischemia-
reperfusion without additional treatment (CON), with inhaled nitric oxide (iNO), with 
gastric tadalafil administration (TAD, 4 mg/kg single bolus), or with combined treatment 
(iNO+TAD). Subgroups of mice were euthanized immediately after NO inhalation (80 
min), at three days for analysis of myocardial infarct size (IS) and myeloperoxidase-positive 
(MPO) cell infiltration and at four weeks after LAD occlusion for transthoracic 
echocardiography (TTE) and pressure volume (PV) catheterization. 
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n4w=15, Figure 4). An additional subset of mice in these 4 groups was studied after 3 
days to evaluate infarct size and determine inflammatory cell infiltration. Nitric oxide 
(Ino Therapeutics LLC, Hampton, NJ, 80 ppm in room air) was administered through an 
intratracheal tube during mechanical ventilation and was started 30 minutes prior to and 
continued for 20 minutes after reperfusion. Dose and timing of NO inhalation was based 
on previously reported results (Hataishi et al., 2006). Tadalafil (Kemprotec Ltd., 
Cumbria, UK) dissolved in 30% solution of 2-hydroxypropyl-β-cyclodextrin (#C0926, 
Sigma-Aldrich) was administered via gastric gavage (4mg/kg) one hour prior to I/R, 
which was determined based on previously reported interspecies dose extrapolations. 
(Ahmad et al., 2009; Salloum et al., 2009; Koka et al., 2010) To determine acute cardiac 
cGMP responses to myocardial ischemia during different treatment regimens, an 
additional subset of animals (n=6-8 per treatment arm) was euthanized 20 min after 
reperfusion (Figure 4).  
3.1.3. Echocardiography  
Transthoracic echocardiography (TTE) was performed using a MS 400 transducer 
(18-38 MHz) connected to a Vevo 2100 scanner (Visualsonics Inc., Toronto, Canada) in 
anesthetized (2% isoflurane in oxygen, Ecuphar, Oostkamp, Belgium), temperature-
controlled mice. Recordings were evaluated using the Vevo dedicated cardiac software 
and LV dimensions at end-diastole (LVIDd) and end-systole (LVIDs), interventricular 
septum and posterior wall thickness at end-diastole and end-systole (IVSd, IVSs, 
LVPWd, LVPWs) were measured,  wall-thickening and fractional shortening (FS) were 
calculated. 
3.1.4 Invasive hemodynamic measurements 
Invasive blood pressure measurement was performed in all animals at day 3 prior 
to vital staining of the myocardium. In mice followed for 4 weeks, invasive pressure-
conductance hemodynamic recordings were performed using urethane, etomidate and 
morphine hydrochloride (1000, 1 and 0.5-1 mg/g body weight, IP) anesthesia 
supplemented with pancuronium bromide (PAVULON, 2 mg/kg IP) neuromuscular 
blockade. Mechanical ventilation was performed using room air at tidal volume 7 µL/g 
BW (MiniVent, Hugo Sachs Elektronik, Germany) and fluid homeostasis was supported 
by 80-100 µL/30g infusion of 15% albumin in physiologic saline and body temperature 
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was maintained at 37oC using an infrared lamp connected to a T-thermocouple rectal 
probe (Hugo Sachs, Germany).  A 1.0-F pressure-conductance catheter (PVR1035, Millar 
Instruments, TX) was inserted in the LV via the right carotid artery and steady-state LV 
pressure-volumes were recorded after 10 min stabilization. To obtain occlusion loops 
with progressively lowering preload, the inferior vena cava was compressed between liver 
and diaphragm with a cotton swab without opening the abdomen. Parallel conductance, 
attributable to cardiac muscle and connective tissues was recorded after infinitesimal 
volume (5-6 µL 15% NaCl solution) IV injection and deducted from the total volume.  
After all measurements were completed, blood was withdrawn from the inferior vena 
cava using a 24G heparinized needle and used for cuvette calibration. Recorded 
measurements were evaluated using the P-V module of the Chart software version 7.5 
(ADInstruments, UK). All data were inferred from the average of measurements with 
breath holding during the expiratory phase. Each measurement represents at least 10 
successive baseline loops. Indices of systolic and diastolic function were calculated 
including stroke volume (SV), cardiac output (CO), ejection fraction (EF), stroke work 
(SW), preload-recruited stroke work (PRSW), arterial elastance (Ea), ventricular 
elastance (Ees), ventricular-arterial coupling (Ea/Ees ratio), maximum and minimum 
rates of systolic pressure rise or decline (dP/dtmax and dP/dtmin) and the time constant 
of isovolumic relaxation (τ) according to Weiss’ method. 
3.1.5. Measurement of infarct size and myocardial necrosis  
Three days after I/R, a subset of mice was re-anesthetized and the initial left 
thoracotomy was reopened. To delineate the perfused area, blue tissue marking dye 
(24111 Marking Dye for Tissue, Polysciences Inc., Warrington, PA) was injected via the 
right carotid artery following repeated ligature of the LAD.  Saturated potassium chloride 
was injected and hearts were excised and embedded into low-gelling temperature agarose 
blocks (Agarose Type VII-A, #0701, Sigma). Specimens were cut into 500-µm thick 
slices using a vibratome (VT1000S, Leica Microsystems, Diegem, Belgium) and stained 
with triphenyl tetrazolium chloride (TTC) for 5 minutes at 37oC.  White colored infarcted 
versus blue colored non-ischemic and red colored risk area (AAR) were identified on 
digital images (Canon EOS 5D camera, EF 100mm f/2.8 Macro USM lens) and analyzed 
by planimetry. 
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To determine myocardial necrosis, circulating troponin I (TnI) was measured in 
plasma retrieved from mixed tail blood samples from sedated animals before I/R 
(Baseline) and 4, and 24 hours after I/R. Plasma TnI was measured using ELISA (#2010-
1-HSP, Life Diagnostics, West Chester, PA) according to the manufacturer’s instructions. 
3.1.6. Measurement of tissue and circulating cGMP levels 
Blood samples were collected using isoflurane anesthesia into 3-isobutyl-1-
methylxanthine-containing tubes (150 µM final concentration) and plasma fractions were 
archived. Following euthanasia by cervical dislocation, LVs were pulverized using liquid 
nitrogen and extracted using 500 µL 6% trichloroacetic acid followed by 3 isovolumic 
extractions of water-saturated diethyl ether. Aquatic fractions were lyophilized and used 
for cGMP measurements. Plasmatic and cardiac cGMP levels were determined using 
Biotrack cGMP enzyme immunoassay (RPN 226, GE Healthcare, Belgium) according to 
the manufacturer’s instructions.  
3.1.7. Measurement of nitric oxide-derived oxidative end products  
In blood samples collected 20 min after I/R, plasma was separated and 
supplemented with N-ethylmaleimide (8 mM final concentration) to protect thiol-groups 
and stored frozen at -80 oC until analysis. Nitrites (NO2-) were reduced using the triiodide 
reagent, while nitrites, nitrates and S-nitroso compounds expressed as NOx were 
converted using vanadium (III)-chloride to NO, followed by ozone-based 
chemiluminescence measurement in line with the Sievers Model 280i analyzer (GE 
Analytical Instruments, Boulder, CO) as described previously. (Yang et al., 2003; 
MacArthur et al., 2007) Cardiac tissue collected 20 min after reperfusion was 
homogenized under liquid nitrogen and extracted in T-PER reagent (#78510, 
ThermoFisher Scientific). Protein concentration was measured by bicinchoninic acid 
assay (BCA assay, #23227, ThermoFisher Scientific) and adjusted to 5 mg/mL. 3-
Nitrotyrosine content was determined in cardiac extracts and plasma using OxiSelect™ 
Nitrotyrosine ELISA Kit (Cell Biolabs Inc, San Diego, CA).  
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3.1.8. Histological and immune-histochemical determination of collagen 
deposition and myeloperoxidase-positive cell infiltration  
To assess mononuclear cell infiltration 3 days after I/R, myeloperoxidase (MPO) 
staining was performed using rabbit anti-human MPO antibody (#A0398, Dako, 
Belgium). Mosaic scans of MPO-stained LV sections were used to count the number of 
cells infiltrating the LV septal and LV free wall at three different planes distal to the site 
of LAD ligation. Collagen deposition was measured in a semi-quantitative manner on 
Sirius red-stained myocardial sections at three different planes and related to LV tissue 
area. Analysis was performed using color thresholding: red color attributable to interstitial 
collagen was quantified, related to LV area and expressed as the average relative collagen 
percentage for each animal. Mosaic images were scanned using the automated Mozaix 
function of the AxioVision 4.6 software on an AxioVert 200 microscope (Carl Zeiss, 
N.V., Zaventem, Belgium) and different myocardial planes were evaluated using the 
ImageJ software (ver. 1.47s, NIH, Bethesda, MD). 
3.1.9. Statistical analysis 
All data are expressed as mean ± SEM. Differences between groups were 
determined using one-way ANOVA with Bonferroni’s post-hoc test. For time-dependent 
follow-up of cTnI, two-way ANOVA with Dunnett’s test for multiple comparisons versus 
untreated CON was applied. Non-Gaussian distributed MPO-cell infiltration data were 
compared using Kruskal-Wallis method with Dunn’s post-hoc test. Probability value of 
p<0.05 for all tests was considered statically significant. Statistical analysis was 
performed using GraphPad Prism 6 software (ver. 6.04, GraphPad Inc., La Jolla, CA). 
3.2. Clinical study on the role of NOS3 polymorphisms in physiologic 
adaptation in elite athletes 
3.2.1. Selection of candidate individuals and study protocol 
Hungarian athletes were screened and selected on the basis of event/sport 
participation, high level qualification and recent international representation. Inclusion 
criteria consisted of at least 10 years of national and 3 years of international qualifications 
(world championships and / or Olympic Games). (Figure 5.) Athletes with VO2 
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maximum greater than 50ml/kg/min during cardiopulmonary stress test using a bicycle 
ergometer were referred to cardiac magnetic resonance (cMRI). Eight players were 
excluded due to low VO2 maximum (<50ml/kg/min) and eleven athletes did not complete 
the cardiac magnetic resonance examination (cMRI) due to intolerance (Figure 5.). Sport 
disciplines with mixed exertion load, including speed, strength and endurance 
components were selected, therefore water polo players (n=48), kayakers (n=21), 
canoeists (n=19), rowers (n=22) and swimmers (n=16) were involved. Majority of the 
water polo players were Olympic level athletes (36/48), while in the kayaker group 10/21, 
in the canoeist group 11/19, in the rower group 12/22 and in the swimmer group 13/16 
Olympic level athletes – among them 39 gold medalists - were screened. Training 
protocol of all examined sportsmen contained mainly strength training. Age and sex 
matched individuals (n=162) were screened for the control group. Since lower VO2 
maximum consumption level (<50ml/kg/min) was part of the inclusion criteria in this 
group, control individuals with higher than 50ml/kg/min VO2 maximum (n=3) were 
excluded from the study and four volunteers who could not tolerate cMRI (n=4) were not 
able to complete the study protocol.  
In this study, all athletes belong to the same ethnic group, are subjected to similar 
environmental factors including dietary habits, smoking status (only 6/126 athletes were 
active smokers during the study), duration of elite athletic status and timing (during 
season) of the examinations. 
3.2.2. Screening protocol 
Stress test was performed in both athletes and non-athletes using a bicycle 
ergometer with an “all-out” protocol. Athletes with a VO2 maximum greater than 
50ml/kg/min and controls with VO2 maximum lower than 50ml/kg/min were referred for 
cardiac magnetic resonance imaging. Blood samples for DNA isolation were collected at 
the first visit. Athletes were all tested and measured during their competitive season 
period in two consecutive years. Participation, including cardiac magnetic resonance 
imaging and blood sampling for DNA extraction was voluntary and part of a prospective 
athletic screening program. Written informed consent was collected from all participants 
and approval of the Hungarian Scientific Council National Ethics Committee for 
Scientific Research (ETT-TUKEB 13687-1/2011) was provided before data and samples 
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were used in this study. The Hungarian Scientific Council National Ethics Committee for 
Scientific Research (ETT-TUKEB) is a supreme authority of the Semmelweis University 
Ethics Committee, which received and approved the national level decision. 
3.2.3. Cardiopulmonary stress test  
A continuous ramp test to exhaustion was performed on an electromagnetically 
braked bicycle ergometer (Ergoline Ergometrics 900, Bitz, Germany). The initial exercise 
load was 50 W and increased in a linear ramp pattern with 25 W every 60 seconds. 
Athletes and non-athlete individuals were asked to continuously pedal until exhaustion, 
maintaining constant revolutions-per-minute at 40-50 rpm. Gas exchange parameters and 
ventilatory variables were recorded breath-by-breath (PowerCube, Ganshorn Medizin, 
Niederlauer, Germany). Vital parameters and blood lactate levels were measured before 
Figure 5. Study protocol and selection of candidate individuals. Top level Hungarian 
athletes (n=145) and healthy control individuals were screened. Athletes above and 
controls under a VO2 maximum greater than 50ml/kg/min were referred to cardiac 
magnetic resonance (cMRI). Eight athletes were excluded due to low VO2 maximum 
(<50ml/kg/min) and eleven athletes did not complete the cardiac magnetic resonance 
examination (cMRI) due cMRI intolerance. Control individuals with higher than 
50ml/kg/min VO2 maximum (n=3) were excluded and four volunteers could not tolerate 
cMRI (n=4). 
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and after the stress test. To quantify perceived exertion during physical activity the rating 
of perceived exertion was collected and exhaustion was defined by completing the BORG 
scale.  The Borg scale ranges from 6 to 20, where 6 means “no exertion at all” and 20 
means “maximal exertion”. Numbers, that best describe their level of exertion, are chosen 
by tested individuals and would be expected to coincide with their heart rate (e.g. BORG 
10 = 100 beats/minute) 
3.2.3. Cardiac magnetic resonance imaging (cMRI) 
Cardiac MRI scans were performed on a Philips Achieva 1.5T magnet. (Philips 
Healthcare, Eindhoven, The Nederlands).  The imaging instrument had Dual Nova HP 
gradients (maximum strength: 33/66 mT/m, slew rate: 180/90 mT/m/ms) and running 
software version R2.5.3 and recently R2.6.3. (Philips Healthcare, Eindhoven, The 
Nederlands) Five element cardiac coil was used for signal reception. The MR protocol 
included retrospectively gated balanced steady-state free precession cine movies in three 
long axis orientations (two-chamber, four-chamber and left-ventricular outflow tract 
views) and short axis slices covering both ventricles. Slice thickness was 8mm, while 
inter-slice gap was set to zero. Each cardiac cycle was divided into 25 to 30 phases. 
Triggered blood suppressed T2-weighted spectral inversion recovery (T2w-SPIR) 
sequence was used for edema detection. Delayed enhancement images were recorded in 
the same views as the cine movies to assess abnormal contrast uptake. While 
administering the Gadovist contrast (0.125mmol/kg IV) k-t BLAST (Broad-use Linear 
Acquisition Speed-up Technique) balanced turbo field echo (b-TFE) sequence was used 
to capture rest perfusion datasets of the three long axis slices. Respiratory motions were 
corrected using breath-holds in end-expiration. In selected cases coronary origins were 
depicted using a fat-suppressed 3-dimensional b-TFE sequence utilizing respiratory 
navigator with prospective motion correction. Medis QMASS MR 7.1 and 7.2 (Medis 
medical imaging systems bv, Leiden, The Netherlands) were used for evaluation. 
Endocardial and epicardial contours were traced manually for both the left and the right 
ventricles and volumetric measures (including papillary muscles), ejection fractions, 
maximal end-diastolic wall thickness and maximal end-diastolic wall thickness, left 
ventricular end diastolic volume index ratios were determined (LA Gerche et al., 2011). 
Body height and weight were measured and archived in SI units. Body surface area was 
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calculated using the Mosteller formula based on the subject's weight and height (BSA 
(m2) = (height (cm) x weight (kg)/3600)½). 
3.2.4. DNA extraction and genotyping 
Genomic DNA was isolated from whole peripheral blood with a protease based 
technique (Flexigene DNA System, Qiagen, Hilden, Germany). Samples (1 ml) were 
added to a lysis buffer and were thoroughly mixed and centrifuged. After discarding the 
supernatant, samples were denaturized, DNA was ethanol precipitated and reconstituted 
in the provided buffer. Samples were stored at -80 °C. Estimation of the DNA yield and 
quality control was done by spectrophotometry and determination of the 260/280 
absorption ratio (Nanodrop-2000, Thermo Scientific, Wilmington, USA). Genotyping of 
The Glu298Asp single nucleotide polymorphism (dbSNP: rs1799983, OMIM: +163729) 
was done with RT-qPCR (StepOne Plus, Applied Biosystems). Pre-designed primers 
were provided by Applied Biosystems (kit number: C___3219460_20) and the reaction 
was performed according to the manufacturer’s protocol.  For each run parallel samples 
with positive controls were used. Genetic analysis was performed blinded to patient data, 
with the provided software. Results are presented according to the National Heart, Lung, 
and Blood Institute recommendations on reporting genetic results in research studies 
(Bookman et al., 2006). 
3.2.5. Statistical analysis 
Data are presented as mean ± SD for continuous variables, or n (%) for categorical 
variables. Comparisons between two groups were performed using Student’s t-test for 
continuous variables (MR parameters), chi-square test for categorical data (genotype, 
gender and athletic status). Analysis of variance (ANOVA) indicated that genotype and 
athletic status may influence right ventricular indices (post-hoc test: Tukey HSD). Linear 
regression was used to explore whether gender and genotype are independent predictors 
for changes in right ventricular stroke volume index (RVSVi) and right ventricular mass 
index (RVMi). Multivariate analysis was performed on groups based on genotype and 
athletic status (Aspartate carriers + non-athletes; Non-aspartate carriers + non-athletes; 
Aspartate carriers + athletes and Non-aspartate carriers + non-athletes). P values less than 
0.05 were considered significant. Calculations were performed using the SPSS 22.0 
program package (IBM Corporation). 
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4. Results 
4.1. Murine experiment on potentiation of NO mediated 
cardioprotection with PDE5 inhibition 
4.1.1. Combined therapy with iNO and TAD confers synergistic 
myocardial protection after I/R 
To investigate the respective treatment effect on cardiac myocyte necrosis markers, 
we measured peak troponin I release at 4h and at 24h after reperfusion. After 4h, peak 
plasma TnI levels were significantly reduced by iNO (n=9; 17.6±5.1 ng/l) and TAD (n=7; 
17.3±5.0 ng/l) compared to untreated CON animals (n=9; 24.6±5.3 ng/l). This effect was 
further amplified in the combined iNO-TAD treatment arm (n=9; 11.4±2.4 ng/l), resulting 
in greater than 50% reduction in peak TnI levels 4h after reperfusion (Figure 6.).  
To evaluate the effect of pharmacologic intervention on myocardial inflammatory 
cell infiltration and tissue damage, we determined the number of myeloperoxidase-
positive cells and the extent of infarcted area relative to risk area three days after I/R. The 
Figure 6. Troponin I (TnI) plasma levels after I/R. Cardiac TnI release increased 
significantly compared to baseline after the LAD-ligation and peaked at 4h after 
reperfusion followed by a marked decline within 24 hours. TAD (n=7), iNO (n=9) and 
iNO+TAD (n=9) treatments all significantly reduced TnI levels compared to non-treated 
CON (n=9) with most prominent effect achieved in iNO+TAD group. * P<0.05, ǂ P<0.001 
vs CON. 
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risk area (AAR) encompassed 57% of the LV area in all groups and did not compromise 
hemodynamic status or early survival (Table 4.).  
 
Table 4. Invasive LV blood pressure measurements 3 days after I/R. 
  
  HR LVPmax LV dP/dtmax LV dP/dtmin  
Treatment N= (BPM) (mmHg) (mmHg/s) (mmHg/s) 
CON 19 612±10 84±3 8584±638 -6727±509 
TAD 14 620±17 82±4 9083±946 -6259±521 
iNO 11 609±11 81±3 8322±636 6148±312 
iNO+TAD 13 625±1 84±3 9038±1087 6512±625 
 
HR- Heart rate in beats per minute (BPM); LVPmax – left ventricular maximal pressure, 
dP/dtmax and dP/dtmin- peak rate of systolic pressure rise and decline. Measurements were 
conducted in the left ventricle. All data are presented as mean ± SEM. 
 
The TTC-stained non-viable area within the AAR was significantly smaller in 
TAD (n=8), iNO (n=5) and iNO-TAD (n=5) animals (27±4%, 22±3% and 24±4%, 
respectively, versus 43±2% in non-treated CON (n=7) mice, P<0.05 for all).  Limited 
discriminatory power of TTC stains and small sample size did not allow further 
differentiation between treatment groups (Figure 7).  
To evaluate the effect of iNO and TAD during I/R on subsequent long term LV 
structural and functional remodeling, we measured LV dimensions and fractional 
shortening after 4 weeks using transthoracic echocardiography and performed pressure- 
volume analysis (Figure 8.) 
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Figure 7. Planimetric analysis of TTC-stained heart sections. All 3 treatment strategies 
significantly reduced infarcted area (IA) expressed relative to the area at risk (AAR) when 
compared to non-treated CON animals (panel A).  Area at risk expressed as percentage 
of LV area (AAR/LV area) was comparable in all groups (Panel B; CON n=7, TAD n=8, 
iNO n=5, iNO+TAD n=5). * P<0.05, ** P<0.01 vs CON 
 
 Pressure-volume analysis showed a significantly greater stroke volume in mice 
treated with iNO+TAD, resulting in a proportionately higher cardiac output at comparable 
heart rates between groups (Table 6.). Mice who inhaled NO had an intermediate response 
with a lesser increase in SV and CO, but higher LV end-systolic pressure and stroke work. 
Increased preload-recruitable stroke work, a load-independent parameter of contractility, 
failed to reach statistical significance in iNO+TAD, suggesting that increased stroke 
volumes may also be accounted for by altered loading conditions (e.g. lower arterial 
elastance, an index of ventricular afterload) independent of better preserved inotropy. 
Ventricular elastance, Ees, which defines the end-systolic pressure-volume relation and 
LV end-systolic stiffness and is considered a useful marker of acute changes in contractile 
function (Pacher et al., 2008), did not differ appreciably between groups in the chronic 
post-infarction phase 4 weeks after reperfusion and remained in what is considered the 
normal range in mice. This is consistent with the absence of overt systolic heart failure in 
the present I/R model. Consequently, ventricular-vascular coupling indexed by the Ea/Ees 
ratio did not show major differences between groups. Diastolic function parameters, 
including LVEDP, dP/dtmin and isovolumic relaxation time index () were comparable 
between CON and treated groups (Table 6.) and consistent with comparable interstitial 
collagen deposition pattern (Figure 9.). 
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Table 6. Pressure-volume analysis of cardiac function at 4 weeks.  
  CON TAD iNO iNO-TAD 
 (n=11) (n=13) (n=12) (n=13) 
HR (BPM) 601±12 604±14 603±15 609±13 
LVESP (mmHg) 78±3 85±4 89±2* 82±3 
LVEDP (mmHg) 2.4±0.6 2.1±0.3 3.5±0.7 2.3±0.5 
SV (µL) 10.2±0,9 11.0±1.1 13.6±1.1 14.9±1.2* 
CO (µL/min) 6129±566 6637±713 8277±707 9156±773* 
EF (%) 50.6±4 54±4 54±4 59±3 
SW (mmHg x µL) 771±85 932±91 1205±97* 1134±119 
PRSW 69±8 71±6 75±10 94±8 
Ea (mmHg/µL) 7.8±1.1 7.0±0.5 6.3±0.7 5.7±0.3 
Ees (mmHg/µL) 10.1±2.8 10.3±1.5 6.7±1.1 9.1±2.2 
Ea / Ees 1.01±0.16 0.79±0.09 1.10±0.14 0.83±0.13 
dP/dtmax (mmHg/s) 8795±946 9956±646 11899±879 10617±969 
dP/dtmin (mmHg/s) -7498±538 -8248±586 -8930±822 -7837±396 
 (ms) 5.2±0,2 5.2±0.2 5.0±0.3 5.1±0.2 
 HR- Heart rate in beats per minute (BPM); LVESP and LVEDP - left ventricular end 
systolic and end diastolic pressures; SV-stroke volume, CO- cardiac output; EF- ejection 
fraction; SW- stroke work; PRSW-preload-recruitable stroke work; Ea- arterial elastance; 
Ees – left ventricular end-systolic elastance; Ea/Ees ratio - ventricular-arterial coupling; 
dP/dtmax and dP/dtmin- maximum and minimum of systolic pressure change over time; - 
tau time constant of isovolumic relaxation according to Weiss’ method. All data are 
presented as mean±SEM. CON = untreated mice, TAD = Tadalafil, iNO = inhaled nitric 
oxide, iNO+TAD = combination therapy. * P<0.05 versus CON  
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Figure 9. Histomorphometric analysis of LV collagen content. Collagen deposition was 
measured in a semi-quantitative manner on Sirius red-stained myocardial sections at three 
different planes and related to LV tissue area. Four weeks after ischemia-reperfusion (I/R) 
minimal reduction (non significant) of fibrosis was observed in all treatment groups 
(panel E). CON (panel A) = untreated mice; TAD (panel B) = Tadalafil; iNO (panel C) = 
inhaled Nitric Oxide; iNO+TAD (panel D) = combination therapy; black arrows point to 
the enlarged areas. 
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4.1.2. iNO and tadalafil treatment modulate NO-cGMP signaling and 
cardiac nitrosative stress 
After inhalation, NO readily forms nitrates, nitrites, nitrosothiols, and iron-nitrosyl 
adducts, collectively measured as NOx. Upon reaction with superoxide, NO also forms 
peroxynitrites, which modify tyrosine residues of various proteins.  Plasma NOx levels 
measured in mice immediately after inhalation of iNO with or without TAD were 5- to 6-
fold higher than in mice who did not inhale NO (P<0.0001 for both, Figure 10.A). 
Similarly, plasma nitrite concentrations in iNO and iNO+TAD were more than 3-fold 
higher than in CON and TAD (P<0.0001 for both, Figure 10.B).  Of interest, nitrotyrosine 
content in the immediate reperfusion period trended to be lower in reperfused cardiac 
tissue after inhalation of NO with or without TAD (P=0.10 and 0.08, respectively, Figure 
4D), while the effect was not detectable in plasma (Figure 10.C). 
NO inhalation and PDE5-inhibition also increase cGMP bioavailability via 
stimulation of guanylate cyclase-mediated synthesis and prevention of 
phosphodiesterase-mediated cyclic nucleotide breakdown, respectively. To study 
whether cardioprotection was associated with increased cGMP bioavailability, we 
measured circulating and cardiac cGMP levels immediately after iNO administration was 
completed. Plasma cGMP levels showed an approximately 20% non-significant increase 
after iNO and TAD treatments (48±3 pmol/mL [n=8] and 51±7 pmol/mL [n=6], 
respectively) versus 38±6 pmol/mL [n=7] in CON, but nearly doubled after iNO-TAD 
(80±12 pmol/mL [n=7], P<0.01 vs CON and iNO, P<0.05 vs TAD). In parallel, cardiac 
tissue cGMP level increased significantly only after iNO-TAD treatment (iNO-TAD 
0.15±0.02 pmol/mg [n=7] vs 0.05±0.01 pmol/mg in CON [n=7], P<0.01), while the 
increase with either iNO 0.07±0.01 pmol/mg [n=6], or TAD 0.10±0.02 pmol/mg [n=8] 
alone did not reach statistical significance (Figure 10.E-F). 
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Figure 10. NO-derived oxidation products, 3-Nitrotyrosine and cGMP levels in 
plasma and in cardiac tissue at 20 min after reperfusion. Plasma levels of NOx, 
comprising nitrates, nitrites and S-nitroso compounds (Panel A) and nitrite (NO2-, Panel 
B) are measured using chemiluminiscence analysis in CON (n=8), TAD (n=7), iNO 
(n=7), and iNO+TAD (n=8) groups. Nitrosative stress is evaluated by measuring proteins 
in circulation or in cardiac tissue containing 3-nitrotyrosine residues (3-NT) using ELISA 
(Panel C-D). Circulating and cardiac cGMP contents were measured using enzyme 
immunoassay (Panels E-F). Plasma cGMP increased after iNO+TAD (n=7; P<0.01 vs 
CON and P<0,05 vs iNO) treatment, while TAD (n=6) and iNO (n=8) did not differ 
significantly from CON (n=7). Similarly iNO+TAD (n=7), but not TAD (n=8) or iNO 
(n=6), significantly increased tissue cGMP levels vs CON (P<0.01, panel F). CON = 
untreated mice, TAD = Tadalafil, iNO = inhaled nitric oxide, iNO+TAD = combination 
therapy. *** P<0.0001 vs CON and TAD, ** P<0.01 vs CON, † P<0.05 vs iNO 
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4.1.3. Combined iNO and TAD therapy attenuates myocardial leukocyte 
infiltration, but not myocardial fibrosis. 
To investigate additional mechanisms of cardioprotection, we analyzed myocardial 
infiltration of myeloperoxidase-positive cells using immunohistochemical stains, an 
established marker of the inflammatory reaction after I/R injury. After 3 days, the number 
of MPO-positive cells relative to mid-ventricular transversal tissue areas was significantly 
lower in iNO+TAD treated mice (P=0.02 vs CON, Figure 11.), but not in iNO- or TAD-
treated mice.  
Four weeks after I/R, we measured collagen fiber deposition in ~7% of the ischemic 
LV area, which was mostly restricted to the mid-ventricular wall and did not vary with 
treatment assignment. In the absence of transmural infarction, the interstitial fibrosis did 
not result in extensive adverse LV remodeling causing significant impairment in 
contractile function, as is usually observed after permanent LAD ligation. (Figure 9.) 
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Figure 11. Myeloperoxidase-positive (MPO) cell infiltration three days after ischemia-
reperfusion. MPO expressing cells (marked by arrow) infiltrate the ischemic area shown 
on a representative image (panel A). The composite image from the immunostained 
transversal myocardial section was assembled from mosaics (MozaiX, AxioVision) and 
contains an inlet with higher magnification of the black framed area. Treatment with 
iNO+TAD (n=6) significantly reduced MPO-positive cell infiltration compared to CON 
mice (n=5), while iNO (n=6) or TAD (n=7) had only a modest effect (Panel B). MPO-
positive cells were counted on 3 different mid-ventricular transversal sections, averaged 
and expressed relative to the LV section area.  CON = untreated mice, TAD = Tadalafil, 
iNO = inhaled nitric oxide, iNO+TAD = combination therapy. * P<0.05 vs CON 
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4.2. Clinical study on the role of NOS3 in physiologic adaptation in 
elite athlethes 
4.2.1. Characteristics of athletes and control individuals 
Elite athletes, including men (n=94) and women (n=32) and Hungarian non-athletic 
controls (n=109 men and n=46 women) were screened. Age distribution and gender ratio 
(25.4% and 29.7% female in athletes and non-athletes, respectively) were not different 
between the study groups. Height, weight and body mass index were higher in men versus 
women and in athletes versus non-athletes. Body surface area, an important value in the 
interpretation of cardiac magnetic resonance imaging results, was also higher in athletes 
when compared with non-athletic controls (Table 7). 
4.2.3. Cardiac morphology and function in athletes and controls 
Left ventricular end diastolic and end systolic volumes and left ventricular 
myocardial mass, indexed to body surface area (LVEDVi, LVESVi, LVMi, respectively) 
were significantly higher in athletes than in the non-athletic group, suggestive of eccentric 
hypertrophy (Table 8). Resting LV ejection fraction (LVEF %) was not different between 
athletes and non-athletes (58.5±6.3% versus 59.4±4.3%, respectively, NS), but LV stroke 
volume index (LVSVi) was higher in athletes than in untrained controls (67.6±8.3 versus 
54.8±7.8 ml/m2, p<0.0001). There were significant gender-related differences with 
higher end-diastolic and end-systolic LV volumes and larger LV mass in men versus 
women, irrespective of athletic activity (Table 8.). Similarly, RV end-diastolic and end-
systolic volume indexes (RVEDVi, RVESVi) were higher in athletes compared to non-
athletes and again, higher in men than in women (Table 8.). Resting RV stroke volume 
index (RVSVi) and RV mass index (RVMi) were both higher in athletes compared to 
non-athletes (for RVSVi 68.2±10.2 versus 56.7±7.0 ml/m2 , p<0.05 and for RVMi 
29.9±6.1 versus 24.4±4.3 g/m2, p<0.05). Both, RVSVi and RVMi were higher in men 
than in women. At exhaustion both VO2 maximum, (60±7 versus 40±7 ml/kg/min, 
p<0.0001) and minute ventilation (VE, 150±15 versus 84±39 l/min, p<0.0001) were 
significantly higher in athletes than in non-athletic controls and within each group, also 
significantly higher in men than in women. 
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4.2.4. Genotype distribution 
Allelic distributions in athletes and controls were similar with a 
minor allelic frequency of 0.27 in athletes vs. 0.26 in controls. In 64 athletes the Glu 
homozygous genotype, in 56 the heterozygous while in 6 out of 126 athletes the Asp 
homozygous genotype was found. The genotype distribution was similar in the non-
athletic control group (84/ G/G, 62/ G/A, and 9/ A/A, chi-square=0.62; p=0.73, Table 9.). 
Therefore the investigated SNP did not correlate with athletic status (p=0.59, with OR 
(CI 95) of 0.8 (0.5-1.4). The proportion of the G/G genotype varied between 49 and 57% 
in both genders in both groups. Overall, genotype distributions were in Hardy-Weinberg 
equilibrium for the SNP in the population. 
 
Table 9. Nitric oxide synthase 3 gene 298 Glu/Asp genotype distribution in athletes and 
in non-athlete controls       
 
Athlete 
(VO2 max >50ml/kg/min) 
Non-athlete 
(VO2 max <50ml/kg/min) 
 Men Women Men Women 
GG (Glu/Glu) 46 (49%) 18 (56%) 58 (53%) 26 (57%) 
GT (Glu/Asp) 43 (46%) 13 (41%) 45 (41%) 17 (37%) 
TT (Asp/Asp) 5 (5%) 1 (3%) 6 (6%) 3 (6%) 
 
Number of individuals with different genotypes in the different groups. Percentage in 
brackets represent the allelic frequency within the subgroup. 
 
4.2.5. Association of cardiac structure and function with the NOS3 298 
genotype 
Resting RV stroke volume index (RVSVi) and RV mass index (RVMi) were both 
higher in Aspartate carriers (athletes and non-athletes, n=133) compared to Glutamate 
homozygous participants (athletes and non-athletes, n=148), for RVSVi 60±9 versus 
62±12 ml/m2 (p=0.047, t-test) and for RVMi 26±6 versus 27±6 g/m2 (p=0.019, t-test). 
Athletes carrying the Asp allelic variant had higher right ventricular mass index, 
than those homozygous for the Glu allelic variant (31.7±5.5 versus 27.4±6.0 g/m2, 
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p<0.01, Table 10. and 11.). RVMi represents right ventricular hypertrophy and was 
associated with higher right ventricular stroke volume index (RVSVi) in the Asp allele 
carrier versus the Glu homozygous athlete group (71.1±9.6 versus 64.3±9.8 ml/m2, 
p<0.001, Table 10. and 11.). In non-athletic individuals no association was observed 
between genotype and right ventricular function and mass. Similarly, left ventricular 
function and anatomy was not associated with the genotype in any of the study groups 
(Table 11.). Oxygen consumption at exhaustion (VO2 maximum) was not different 
between the Asp allelic variant carriers and the Glu homozygous individuals, irrespective 
of the athletic status (in athletes 61±8 versus 58±6 ml/kg/min and in non-athletes 40±7 
versus 39±7 ml/kg/min, respectively, NS for both). There was, however, a trend towards 
higher maximal minute ventilation in Asp allelic variant carrier versus Glu homozygous 
athletes (152±13 versus 146±11 l/min, p=0.08). The genotype was not associated with 
ventilation in non-athletes. 
 
Table 10. Characteristics of male and female athletes and athletes with, or without the 
Asp allele 
  
Resting right ventricular 
stroke volume index  
(RVSVi, ml/m2) 
Right ventricular mass 
index (RVMi g/m2) 
 
Gender 
Men 70.7±9.5 ‡ 32.5±4.6 ‡ 
Women 61.5±9.2 23.5±5.4 
 
NOS3 
Glu/Glu 64.3±9.8 27.4±6.0 
Asp carrier 71.1±9.6 # 31.7±5.5 # 
 
In this age matched population of elite athletes with a similar social and ethnic 
background linear regression analysis revealed that both male gender and the presence of 
the Asp allele are independent predictors for higher resting right ventricular stroke 
volume index (RVSVi) and right ventricular mass index (RVMi) values.  (‡ p<0.001 vs 
women, #p<0.001 vs Aspartate carriers)  
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Table 11. Characteristics of different genotypes within athletes and non-athletes 
(irrespective of their gender) 
 
 Athletes (VO2 max 
>50ml/kg/min) 
Non-athletes (VO2 
max >50ml/kg/min) 
 
  
Glu/Glu 
Glu/Asp  
+ Asp/Asp 
Glu/Glu 
Glu/Asp  
+ Asp/Asp 
p 
N 64 62 84 71 - 
LVEF (%) 58.3±8.1 58.7±4.5 59.1±2.4 60.0±6.7 0.688 
LVEDVi (ml/m2) 115.1±20.5  * 117.0±14.9 * 92.1±14.6 94.4±9.3 <0.001 
LVESVi (ml/m2) 49.2±13.3  * 48.5±9.3 * 37.8±7.8 37.9±7.6 <0.001 
LVMi ( g/m2) 77.9±23.1 * 83.5±16.2 * 60.3±15.3 63.2±11.2 <0.001 
LVSVi (ml/m2) 66.4±7.6 * 68.5±8.7 * 54.1±7.6 56.1±8.2 <0.001 
RVEF (%) 57.7±8.1 58.1±4.4 58.3±4.1 58.4±5.8 0.427 
RVEDVi (ml/m2) 117.8±19.9 * 124.4±19.1 * 95.6±17.6 95.4±9.8 <0.001 
RVESVi (ml/m2) 53.0±10.5 * 53.4±12.1 * 40.4±11.0 38.7±6.5 <0.001 
RVSVi (ml/m2) 64.3±9.8 #* 71.1±9.6 * 56.6±6.7 56.8±7.8 <0.001 
RVMi ( g/m2) 27.4±6.0 #* 31.7±5.5 * 25.3±4.7 23.3±3.4 <0.001 
 
n – number of individuals; LVEF – left ventricular ejection fraction; LVEDVi – left 
ventricular end-diastolic volume index; LVESVi – left ventricular end-systolic 
ventricular index; LVMi – left ventricular mass index; LVSVi – left ventricular stroke 
volume index; RVEF – right ventricular ejection fraction; RVEDVi – right ventricular 
end-diastolic volume index; RVESVi – right ventricular end-systolic volume index; 
RVSVi – right ventricular stroke volume index; RVMi – right ventricular mass index 
Analysis of variance showed significant differences among the inspected groups: athletes 
and non-athletes with and without the Aspartate allele. Post hoc tests revealed a 
significant influence of the genotype (# p<0.001 vs Asp carriers within the athlete group) 
on resting RVSVi and RVMi in athletes. Athletic status had significant influence on all 
parameters with the exception of LVEF and RVEF (* p<0.001 vs non-athletes 
irrespective of genotype). 
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5. Discussion 
5.1. Murine experiment on potentiation of cardioprotection from NO 
with PDE5 inhibition  
In this study we report that combining inhalation of NO with oral administration of 
tadalafil (TAD) is safe and confers incremental myocardial protection during I/R injury 
in mice. For a similar risk area, combination therapy was associated with a greater 
reduction in troponin release during the acute phase, and less inflammatory cell 
infiltration when compared to either treatment alone. The early benefit at the time of 
reperfusion translated in markedly improved functional and structural remodeling after 
four weeks. LV end-systolic dimensions following combination treatment were reduced 
and associated with a better-preserved regional LV function on transthoracic 
echocardiography. In addition, invasive pressure volume analysis using conductance 
catheter technology confirmed improved contractile performance in mice treated with 
iNO and TAD with significantly higher stroke volumes. Finally, the superiority of the 
combination therapy was associated with significantly greater nitrite plasma 
concentration, a trend for lower cardiac nitrosative stress levels and significantly higher 
cGMP bioavailability in the heart and in the circulation, emphasizing the importance of 
this second messenger system in cardioprotection. 
 Several laboratories have previously reported that NO inhalation during ischemia 
and reperfusion effectively reduces myocardial infarct size and improves cardiac function 
in rodent and porcine models of I/R (Liu et al., 2007; Nagasaka et al., 2008; Neye et al., 
2012). Moreover, when administered at 80 ppm for 24 hours, iNO prevented early 
increase in left ventricular dimensions and helped to preserve ejection fraction (Hataishi 
et al., 2006). At first glance it seems, that there is a discrepancy between our data and the 
work of Hataishi et al., as we failed to verify the same protection against LV dysfunction 
with iNO treatment alone. There are, however, important differences in study design, 
which could account for this difference. Hataishi and coworkers used the same ischemic 
time (60 min) and concentration of inhaled NO (80 ppm) but exposed their mice to NO 
in a sealed chamber for the entire duration of the experiment (e.g. 24h), while in our study 
NO delivery was limited for 50 minutes. Hataishi and colleagues reported reduced LV-
EDV and better preserved EF at 24h after I/R, a timepoint that reflects early reperfusion 
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injury and cannot be compared to the functional and structural remodeling parameters 
measured at 4 weeks follow up. The lack of cGMP rise in the myocardium in Hataishi’s 
study may be attributable to increased cardiac PDE5 activity which has been shown to be 
up-regulated in the early I/R phase by other groups (Hataishi et al., 2006; Kass, 2012). 
Others have shown that iNO conferred cardioprotection is at least partially cGMP 
mediated, as with the loss of the alpha form of soluble guanylate cyclase, the protective 
effect of NO was lost as well (Nagasaka et al., 2011). These observations are consistent 
with our findings of 100% increased cardiac cGMP content following pretreatment with 
TAD, while iNO alone was only able to increase cardiac cGMP by 50%. Changes in 
cardiac cGMP content during the early reperfusion phase strikingly mirror changes in 
plasma, further supporting the biological significance of these observations. 
In the bloodstream, iNO is rapidly converted to nitrite, nitrate, or to various S- and 
N-nitrosated proteins (Bhatraju et al., 2015; Bloch et al., 2007). Red blood cells serve as 
a major reservoir of nitrite with a bidirectional reversible flux between red blood cell and 
plasma compartments. When exposed to lower hemoglobin oxygen saturations and acidic 
pH in ischemic myocardium, NO can be released from nitrites, hem-nitrosyls and S-
nitrosothiols. Such a selective release of bound NO increases its bioavailability in areas 
of impaired perfusion and could confer cardioprotection (McMahon and Doctor, 2006; 
Neye et al., 2012; Schumacker, 2013; Terpolilli et al., 2012). In this study, we have 
observed 2.5-3 fold increased plasma nitrite levels and 6-7 fold increased total NOx 
levels, which may serve as source of NO. Conversely, NO may interact with superoxide 
radicals to generate peroxynitrites and partially offset cardioprotection or may scavenge 
free radicals and transiently reduce nitrosative stress, as suggested by reduced cardiac 3-
nitrotyrosine levels in the early post-reperfusion phase in mice treated with inhaled NO 
(Figure 10D) (Ferdinandy et al., 2000; Gielis et al., 2011; Szabó et al., 2007). 
 At the same time, inhibition of phosphodiesterases (PDEs), the class of enzymes 
responsible for cGMP degradation, significantly reduced MI size and cardiac dilatation 
and preserved global LV function in mice (Das et al., 2015a; Kass et al., 2007a, 2007b). 
Under physiologic conditions, PDE5 expression levels in the cardiovascular system are 
very low and mainly confined to smooth muscle cells. Upregulation and activation of 
PDE5 was reported in ischemic and failing myocardium, in part via cGMP-dependent and 
PKG-I mediated phosphorylation (Das et al., 2015a; Kass et al., 2007a, 2007b), setting 
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the stage for successful administration of selective PDE5 inhibitors such as sildenafil in 
heart failure with reduced ejection fraction (Das et al., 2015a, p. 5; Guazzi et al., 2011; 
Lukowski et al., 2014; Redfield et al., 2013).  
 We hypothesized that during acute ischemic disease insufficient NO 
bioavailability to stimulate cGMP generation argues against the use of PDE5 inhibition 
as a viable strategy to sufficiently boost cGMP levels. Therefore, in this study we 
investigated whether combined iNO-induced stimulation of sGC with selective inhibition 
of PDE5-catabolized hydrolysis can safely confer cardioprotection. Ligation of the 
proximal LAD resulted in a territory at risk that encompasses more than 50% of the left 
ventricle. This degree of myocardial injury did not compromise hemodynamic stability 
or survival. Stable or very modest reductions in blood pressure were previously reported 
after application of iNO in acute MI (Bloch et al., 2007; Ichinose, 2013; Nagasaka et al., 
2008). Conversely, single dose administration of the long-acting tadalafil was reported to 
have variable effects on blood pressure. In this study, monotherapy with iNO and TAD 
or combined application did not compromise blood pressure, one of the most critical 
parameters during I/R treatment protocols. However, rigorous dose escalation studies 
would be required to determine the most effective dose and the safety margins. 
The applied dose of tadalafil, 4 mg/kg via gastric delivery was approximated from 
human studies and was reported to reach protective plasma concentrations in rodents 
(Ahmad et al., 2009; Koka et al., 2014; Salloum et al., 2014, 2009; Sesti et al., 2007). 
Some groups have used a higher dose of tadalafil (10mg/kg) 2h before coronary artery 
occlusion. The duration of occlusion was also shorter, 30 minutes compared to 60 minutes 
in our study (Sesti et al., 2007). Koka and coworkers reported on mice treated for 9 
consectuvie days with oral gavage of tadalafil (4 mg/kg), in which they were able to 
measure a tadalafil plasma concentration of 534±89 ng/mL 1h after the last drug-
administration (Koka et al., 2010). This dose was chosen based on the interspecies dose 
extrapolation scaling and would result in plasma concentrations equivalent to a human 
dose of 20 mg/day.   
We measured a significant rise in plasma and cardiac cGMP levels only in animals 
that received combination therapy. Plasmatic cGMP does not necessarily reflects the 
cGMP bioavailability in organs, but increased cGMP signaling in the ischemic heart 
confers protection by attenuating -adrenergic-stimulated  contractility, preventing 
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progression of Ca2+-triggered Ca2+ waves and limiting GAP-junction communication 
during cell-to-cell propagation of necrosis (Francis et al., 2010).  
In addition to direct effects on cardiac myocytes, cGMP also affects multiple other 
pathways involved in I/R injury including platelet activation, vasorelaxation, expression 
of adhesion proteins and endothelial permeability, and neutrophil activation (Garcia-
Dorado et al., 2009). The latter effect together with monocyte to macrophage 
differentiation is reflected by increased MPO-levels (Hataishi et al., 2006; Liu et al., 
2007). Several mechanisms have been reported in the literature to account for the effect 
of NO on polymorphonuclear inflammatory cells: NO limits leukocyte chemotaxis, 
adherence and activation (Kubes et al., 1991). The mechanism may involve suppression 
of relevant circulating chemokines and expression of adhesion molecules. Inhaled NO or 
NO released after NOS3 gene transfer in a porcine model diminished MPO-activity and 
reduced the expression of intercellular endothelial adhesion molecule-1 (ICAM-1) 
expression in cardiac tissue (Liu et al., 2007; Szelid et al., 2009). Endogenous and 
exogenous NO dose-dependently reduces the release of interleukin 8 (IL-8), the main 
chemo-attractant factor of neutrophils (Cuthbertson et al., 1997). Moreover, in the 
coronaries of eNOS-deficient mice after I/R the expression of P-selectin was increased 
and exacerbated the adhesion of neutrophils (Jones et al., 1999). Leukocyte adhesion is 
at least partially mediated by the soluble guanylate cyclase (sGC), which was proven in 
vivo using the sGC activator BAY-41 2272 (Belhassen et al., 2001; Boerrigter and 
Burnett, 2007). More recently, TAD therapy has also been shown to ameliorate 
circulating inflammatory cytokines and chemokines (Varma et al., 2012). We observed 
reduction in MPO-positive cell infiltration exclusively after combined treatment and saw 
that following inhalation with or without concomitant TAD there is a trend for reduced 
cardiac 3-nitrotyrosine levels during the early reperfusion period. Unfortunately, whether 
reduced nitrosative stress is a cause or consequence of altered MPO-positive cell 
infiltration cannot be determined from our experiments. 
At the molecular level, cGMP-dependent activation of protein kinase G-I (PKG-I) 
enhances ERK signaling and results in reduced opening probability of mitochondrial 
permeability transition pore (Francis et al., 2010). The latter represents a final common 
switch in the RISK pathway for cellular protection against ischemic damage and may 
partially be mediated through hydrogen sulfide (Das et al., 2015b; Salloum et al., 2009). 
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In our study combination treatment improved LV fractional shortening and prevented 
cardiac remodeling during the 4 weeks follow up period, while either treatment alone had 
only partial effects.  
5.1.1. Limitations 
First, the relatively short follow up period and limited transmurality of the infarction 
in our mice precludes extension of findings on survival and development of heart failure. 
Second, TTC-based planimetry of infarct size was not sensitive enough to discriminate 
between the three treatment groups. To delineate infarct size with greater precision, 
detailed morphometric analysis or high flux density magnetic resonance imaging would 
be required. Third, administration of TAD 60 min prior to I/R does not represent a 
therapeutic situation in mice, but the concept may be useful during clinical translation 
using the time window between MI detection and reperfusion.  
5.1.2. Conclusion 
Combined NO inhalation and selective PDE5 inhibition using tadalafil during 
myocardial ischemia-reperfusion confers superior protection against I/R injury in mice. 
The associated increase in cGMP-signaling after the combined treatment suggests the 
importance of this pathway for beneficial long-term structural and functional remodeling. 
Combined therapy may represent a promising strategy for translational research to 
improve the outcome of ischemia-reperfusion injury in patients. 
5.1.3. Potential influence on human ischemia reperfusion therapy 
Attenuating ischemia reperfusion injury is of major interest and in the last decades 
several attempts were made to breach this barrier (Ovize et al., 2013). Preconditioning 
has no clinical relevance, but remote-, post- and pharmacological post-conditioning are 
potential therapeutic means. 
Our data suggest that inhaled NO therapy should be introduced at least 10-15 min 
before the reperfusion to effectively impact on mechanisms of reperfusion injury. Nitric 
oxide reaches the bloodstream very rapidly through the alveolar-capillary barrier and is 
transmitted to the ischemic tissues via NO-heme adducts, nitrites or S-nitrosylated 
proteins. Human pharmacokinetic studies demonstrated that tadalafil is a selective PDE-
5 inhibitor, whose effects can last up to 36 hours (compared to sildenafil’s and 
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vardenafil’s effects lasting for 4 to 8 hours). Tadalafil is also the only PDE-5 inhibitor 
whose activity is unaffected by food and has a relatively short time to onset of action (16 
to 17 minutes). The pharmacokinetic profile of tadalafil shows maximal plasma 
concentration within 2.0 hours and an elimination half-life of 17.5 hours.  
In STEMI pateints with normal systemic blood pressure, we would propose that the 
best time for tadalafil administration would be 16-30 min before reperfusion, which 
should provide enough time for NO to exert its cardoprotective effects as well. 
Recently an international, multicenter, randomized, double blinded clinical trial 
was designed and executed by Janssens and coworkers at the Catholic University of 
Leuven to verify beneficial effects of inhaled nitric oxide therapy in patients with acute 
myocardial infarction. The Nitric Oxide for Inhalation in ST-Elevation Myocardial 
Infarction (NOMI) trial, however, failed to achieve reduction in infarct size (primary 
endpoint of the study). Major findings of the trial were improved functional recovery and 
an unforeseen significant interaction between iNO and nitroglycerin. 
5.2. Clinical study on the role of NOS3 in physiologic adaptation in 
elite athletes 
In this study, association between sport-related right ventricular adaptation and the 
Glu298Asp genetic variant of the endothelial nitric oxide synthase 3 gene was examined 
in elite athletes. The NOS3 genotype and its relation with athletic performance and 
physiologic adaptation in selected elite athletes have already been described, however we 
are first to report that physical preconditioning evokes genotype-influenced right 
ventricular adaptation (Hand et al., 2006, p. 3; Rankinen et al., 2000, p. 3; Saunders et al., 
2006). 
Consistent with previous findings, in our study, no difference in genotype 
distribution was found between elite athletes and control individuals (Wolfarth et al., 
2008). According to the dbSNP database Minor allele frequency was lower than in the 
HapMap-CEU population (0.27 vs. 0.34) and comparable with the largest population 
available (PA159018372, 0.27 vs. 0.29). 
Although the adaptation of the left ventricle and its possible functional 
consequences on athletic performance represent a major focus of sport physiology 
research, there is increasing evidence that right ventricular adaptation may be a better 
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marker of athletic performance  (Aaron et al., 2011; Scharhag et al., 2002; Steding et al., 
2010). There is a near linear correlation between exercise intensity and pulmonary artery 
pressures, which results in a disproportionate increase in right, compared to the left 
ventricular afterload (La Gerche et al., 2014). Association between strenuous high 
intensity exercise and a disproportionate enlargement of the right ventricle was observed 
previously. (Maron, 1986; Perseghin et al., 2007). Beside chamber dilation athletic 
adaptation goes together with decreased resting RV ejection fraction and ventricular-
arterial coupling alterations which, in turn, may be an early sign for contractile 
impairment (Claessen et al., 2014). In addition right ventricular mass and volume were 
also independent markers of self-reported physical activity in a recent community-based 
trial (Aaron et al., 2011). These changes in the RV structure represent physiologic athletic 
adaptations, however, extensive remodeling may also predict pathologic conditions. 
Distinguishing physiologic- from pathologic adaptation remains an important and 
challenging task (Ector et al., 2007; La Gerche et al., 2013). Therefore, a careful 
examination of the right ventricle in highly trained individuals is therefore critical, 
although it is not part of the current pre-participation screening protocols  (La Gerche et 
al., 2010).  
Because of its anti-hypertrophic myocardial effects nitric oxide (NO) could affect 
athletic performance via several mechanisms, including improved coupling of cardiac 
oxygen consumption to physical performance, enhanced LV relaxation and decreased LV 
end-diastolic pressure, increased NO-dependent myocardial Ca2+ influx and contractile 
force (Bito et al., 2010; Booz, 2005; Heusch et al., 2000; Matter et al., 1999). The primary 
source of NO is NOS3 in the cardiovascular system. Therefore, Glu to Asp amino acid 
substitution at codon 298 in the NOS3 enzyme and reduced NO production may result in 
altered biological effects, including impaired vasodilation and increased myocardial 
hypertrophy. 
In our study, however, no connection was found between the NOS3 genotype and 
left ventricular parameters neither in athletes, nor in untrained-individuals. Interestingly, 
without a significant effect on maximal oxygen uptake, there was a trend towards higher 
minute ventilation at peak exercise in Asp allelic carrier compared to Glu homozygous 
athletes. This phenomenon was not observed in non-athletes.  
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Bench-side and clinical data support the theory that the hypoxia-induced pulmonary 
vasoconstriction may be further enhanced by the increased cleavage of the Aspartate 
containing NOS3 protein (La Gerche et al., 2014; Tesauro et al., 2000). Under excessive 
chronic load this could hasten the depletion of the marginally sufficient right ventricular 
contractile reserves, which was shown to lead to a disproportionate and exaggerated right 
ventricular remodeling in both animal- and clinical studies  (Benito et al., 2011; La 
Gerche et al., 2014; Modesti et al., 2004). As sustained right ventricular fatigue and injury 
may result in pathologic fibrous remodeling, the clinical significance of our findings 
could lie with their potential influence on the development of RV cardiomyopathy  
(Gerche et al., 2012; Heidbüchel et al., 2003). 
  The influence of the NOS3 Glu298Asp polymorphism on enzymatic cleavage and 
thus NO availability has been shown to reduce treatment efficacy in heart failure patients. 
In a genetic sub-study of the African-American Heart Failure Trial (A-Heft) Glu298Glu 
genotype predominance was associated with the positive impact of NO donors (isosorbide 
dinitrates and hydralazine) on heart failure survival (McNamara et al., 2009; Tesauro et 
al., 2000). 
The NOS3 Glu298Asp polymorphism has also been associated with cardiac 
adaptation to long-term athletic performance. This association included the 
cardiovascular adaptation of untrained individuals to long term endurance training with a 
blunted responsiveness of submaximal exercise, diastolic blood pressure and rate pressure 
product in previously sedentary Asp homozygous subjects.  Higher stroke volume and 
lower heart rate during sub-maximal exercise was reported in postmenopausal women 
carrying the Asp allelic variant (Hand et al., 2006; Rankinen et al., 2000). The NOS3 
Glu298Asp variant was also associated with the actual contest performance in elite ultra-
endurance athletes (Saunders et al., 2006).   
In elite athletes we found larger right ventricular myocardial mass and increased 
RV stroke volume (both indexed to body surface area) in Asp allele carriers versus Glu 
homozygous individuals. The higher stroke volume observed in the Asp carrier athletes 
was associated with a non-significant trend of larger end diastolic volumes compared to 
the Glu homozygous athletes.  
These associations could be the consequences of the increased afterload and adverse 
pulmonary remodeling brought forth by reduced NO bioavailability. Knockout murine 
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experiments highlighted the fact that albeit all three isoforms are present in the lung, 
NOS3-derived NO is the major regulator of pulmonary vascular tone. Loss of NOS3 
function results in a markedly enhanced hypoxic pulmonary vasoconstriction, 
significantly elevates right ventricular pressure and induces airway hyper-responsiveness 
(Fagan et al., 1999; Feletou et al., 2001). In addition, even the endothelial response to ß-
adrenergic stimuli could be compromised and thus protection from sympathetic 
hyperactivity could be hampered (Davel et al., 2015). During the last decade candidate 
gene approach and analysis of single genetic variants became overshadowed by systems 
biology, gene-environmental and gene-gene interaction studies. In the present study 
group however strict inclusion criteria make the analysis of correlations with a single 
genetic variant more plausible.  
5.2.1. Limitations 
Cross sectional study design limits insight on the interaction of the NOS3 
Glu298Asp polymorphism with athletic remodeling. As this study was focused on a 
highly selected group of athletes, individuals from several sports disciplines – although 
with very similar training regimes – had to be screened to reach an acceptable number of 
participants. Given our single gene candidate approach, other polymorphisms in linkage 
disequilibrium with the Glu298Asp polymorphism may be the true cause of this 
association. 
5.2.1 Conclusion 
In this study cardiac function and structure of elite athletes was determined and a 
previously unknown correlation was found between load-dependent right ventricular 
adaptation and a candidate genetic variant, the NOS3 Glu298Asp polymorphism. Our 
study supplements evidence in the literature showing another aspect of NOS3 genotype 
influence on cardiac adaptation. Whether this has a positive or negative effect on the 
individuals’ long term cardiovascular health and athletic performance has yet to be 
determined. Combined use of non-invasive cutting edge imaging modalities and 
genotyping tools may help to track the extent of influence both during training and late 
life deconditioning.  
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Given the high frequency of the nitric oxide synthase 3 gene 298 Glu/Asp 
polymorphism this could have substantial impact if there was more evidence related to its 
functional and long-term implications.  
6. Future directions 
After the NOMI trial’s failure to achieve infarct size reduction and its puzzling 
findings of iNO and organic nitrate interaction, new questions emerge and novel treatment 
plans have to be established. One should, however, keep in mind, that drug interactions 
not only have the potential to nullify damage mitigation, but based on our data they may 
be able to release unexploited reserves of cGMP mediated cardioprotection. Beyond the 
search for an optimal combination of medications, therapy has to be individualy adjusted 
for concomitant diseases and new, most probably functional and not anatomical 
landmarks have to be indentified as markers of treatment efficacy. Potential research 
projects could assess the influence of concomitant diseases (e.g. diabetes mellitus) and 
the interaction among organic and inorganic nitrates or other drugs with influence on the 
cGMP mediated pathway (eg. sGC stimulators). To estimate the exact functional benefits 
of the iNO+TAD combination therapy long term follow up studies with exercise tests end 
less investigator dependent imaging endpoints (eg. cMRI) would be needed. 
It has been proven that genetic heritage has the potential to influence the 
development of athlete’s heart and although single candidate gene approach became 
somewhat outdated, in highly selected populations it may still help to assess genetic 
influence on performance and/or remodelling. To strengthen our data on the influence of 
the NOS3 Glu298Asp polymorphism on right ventricular remodeling proscpective studies 
on reversibility and adverse cardiac events would be needed. Although costly, MRI 
guided and training plan adjusted follow-up studies seem to be feasible, the limited size 
of target population, however, makes it in my opinion almost impossible to conduct 
research with mortality or morbidity end-points.  
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7. Summary  
Nitric oxide signaling has remained on the frontlines of scientific interest in 
cardiovascular physiology and pathophysiology for almost 30 years. Animal models were 
constructed to study various diseases and physiologic adaptations. Numerous signaling 
pathways were identified and their role in cardiovascular regulation was explored. 
Transition to human physiology and pathophysiology resulted in FDA-approved drugs 
that became first line therapy for a variety of diseases. 
Ischemia reperfusion injury, however, remains a field to be conquered. In animal 
models several compounds brought spectacular results in infarct size reduction and 
attenuation of adverse cardiac remodeling. Some of them passed phase I but none of them 
could prove their efficacy in phase II clinical trials. Research presented in this work aimed 
to evaluate the remaining potential of inhaled nitric oxide therapy and the 
NOS/sGc/cGMP signaling pathway.  We found, that concomitant NO inhalation and PDE 
inhibition not only reduced infarct size, but conferred additional functional improvement 
when comapered with standalone treatments. Based on our data we hypothesize that 
cardioprotective signal induction and simultaneous signal stabilization could effectively 
enhance currently available therapeutic approaches.   
Nitric oxide signaling is a key mediator in physiologic cardiac adaptation. It is 
known, that in selected populations individual differences in endogenous NO production 
and bioavailability may be associated with adverse cardiac remodeling and/or athletic 
performance. We were able to identify a previously not known correlation between 
exercise induced right ventricular remodeling and a common NOS3 polymorphism. Our 
findings support previous data on the influence of nitric oxide signaling and NOS 
polymorphisms on athletic adaptation and proved that under special circumstances the 
examined genetic variants may be capable to influence cardiac morphology and function. 
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8. Összefoglalás 
A nitrogén monoxid jelátvitel kardiovaszkuláris élettanra és kórélettanra kifejtett 
hatásainak vizsgálata több mint 30 éve áll a tudományos érdeklődés középpontjában. 
Számos állatmodell áll rendelkezésre a különböző betegségek és a fiziológiás adaptáció 
vizsgálatára. Különféle jelátviteli utakat azok szerepét azonosították a kardiovaszkláris 
rendszer szabályozásban. Mindezen eredmények humán élettanra és kórélettanra 
vonatkoztatása az FDA által is elismert, több betegség kezelésében élvonalbeli szerré 
előlépő hatóanyagok kifejlesztéséhez vezetett. 
Az iszkémia-reperfúziós károsodás csökkentése azonban továbbra is megoldatlan 
megoldatlan maradt. Preklinikai modellekben számos hatóanyag igen látványos 
eredményt ért el az infarktus területének csökkentésében és hatékonyan előzte meg az 
rosszindulatú remodellációt. Néhány hatóanyag sikeresen túljutott a fázis I-es 
vizsgálatokon, azonban a fázis II vizsgálatok során egyik sem bizonyult hatásosnak.  Az 
ebben a dolgozatban bemutatott kísérletes munka célja az inhalált nitrogén-monoxid 
kezelésben és a NOS/sGC/cGMP jelátvitelben rejlő terápiás és diagnosztikus lehetőségek 
vizsgálata volt. Az inhalált NO kombinálása PDE gátlókkal nem mérsékelte az egyes 
szerek infarktus-méretét csökkentő hatását, hanem eredményeink alapján további 
funkcionális javuláshoz is vezetett. Adataink alapján az egyidejűleg kiváltott 
kardioprotektív jelátvitel indukció és jel-stabilizáció tovább fokozhatja a már meglévő 
terápiás lehetőségek hatékonyságát.  
A nitrogén-monoxid a szívizom fiziológiás sport-adaptációjában is kulcsfontosságú 
mediátor. Ismert, hogy bizonyos populáción belül az NO termelés és biohasznosulás 
egyéni eltérései nem csak a remodellációt, de a kardiovaszkuláris szabályozást és a 
sportolói teljesítményt is befolyásolhatják. Vizsgálatunkkal egy eddig nem ismert 
összefüggést tártunk fel a testmozgás indukálta jobb kamrai remodelláció és egy jól 
ismert NOS3 polimorfizmus között. Eredményeink tovább erősítik azokat a korábbi 
megfigyeléseket, amik szerint a nitrogén-monoxid jelátvitel és a NOS polimorfizmusok 
aktív szerepet tölthetnek be a sport-adaptációban és igazoltuk, hogy ilyen különleges 
körülmények között a NOS gén genetikai variánsai képesek a szív morfológiájának és 
működésének befolyásolására.   
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Supplement 
 Differences in both disease models and species make comparisons extremely 
difficult and all conclusions have to be treated with extreme caution. With all this in mind, 
I believe my work complements already available data on the importance of NO signaling 
under unusual circumstances. It may be safe to say that both ischemia reperfusion injury 
and extreme athletic performance put additional load on viable myocardium and 
accumulate free radicals in the myocardium. In both settings, better nitric oxide 
availability was associated with beneficial effects on cardiac remodeling. Lack of data on 
nitric oxide availability and cGMP levels in our human participants makes mechanistic 
comparisons impossible. Luckily extreme athletic performance associated free radical 
accumulation is known, thus we can make speculations. In addition to changes in the 
lesser circulation, it is not unthinkable that NO mediated scavenging of free radicals also 
conferred some cardioprotection for our athletes carrying the Asp allele. At this point 
there might be similarities between murine experiments and human observations, as in 
mice we were able to document beneficial changes in NOx and nitrotyrosine levels after 
NO inhalation. The role of cGMP signaling remains debatable, but if we accept the idea 
of increased NO levels in Asp carriers (it was not measured), than there might be 
differences in cGMP availability as well. In this case cGMP mediated alteration of cardiac 
remodeling, just as in murine I/R models, might be present as well. 
There are however too many differences between my experiments, thus I would 
refrain myself from translating inhaled NO mediated I/R injury reduction into a potential 
complementary performance-enhancing treatment for athletes. 
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